<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28441966</article-id><article-id pub-id-type="pmc">5405502</article-id><article-id pub-id-type="publisher-id">1904</article-id><article-id pub-id-type="doi">10.1186/s13063-017-1904-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Maintenance tegafur-uracil versus observation following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection: study protocol for a randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yeh</surname><given-names>Yung-Sung</given-names></name><address><email>920055@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Tsai</surname><given-names>Hsiang-Lin</given-names></name><address><email>chunpin870132@yahoo.com.tw</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Ching-Wen</given-names></name><address><email>baseball5824@yahoo.com.tw</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Wei</surname><given-names>Po-Li</given-names></name><address><email>poliwei@tmu.edu.tw</email></address><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Sung</surname><given-names>Yung-Chuan</given-names></name><address><email>yungchuans@cgh.org.tw</email></address><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Hsiu-Chih</given-names></name><address><email>schoetz.tang@gmail.com</email></address><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wang</surname><given-names>Jaw-Yuan</given-names></name><address><phone>+886-7-3122805</phone><email>cy614112@ms14.hinet.net</email><email>jayuwa@cc.kmu.edu.tw</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff11">11</xref><xref ref-type="aff" rid="Aff12">12</xref><xref ref-type="aff" rid="Aff13">13</xref><xref ref-type="aff" rid="Aff14">14</xref><xref ref-type="aff" rid="Aff15">15</xref></contrib><aff id="Aff1"><label>1</label>Division of Trauma and Critical Care, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan </aff><aff id="Aff2"><label>2</label>Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan </aff><aff id="Aff3"><label>3</label>Department of Emergency Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9476 5696</institution-id><institution-id institution-id-type="GRID">grid.412019.f</institution-id><institution>Graduate Institute of Clinical Medicine, College of Medicine, </institution><institution>Kaohsiung Medical University, </institution></institution-wrap>Kaohsiung, Taiwan </aff><aff id="Aff5"><label>5</label>Division of General Surgery Medicine, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9476 5696</institution-id><institution-id institution-id-type="GRID">grid.412019.f</institution-id><institution>Department of Surgery, Faculty of Medicine, College of Medicine, </institution><institution>Kaohsiung Medical University, </institution></institution-wrap>Kaohsiung, Taiwan </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9476 5696</institution-id><institution-id institution-id-type="GRID">grid.412019.f</institution-id><institution>Graduate Institute of Medicine, College of Medicine, </institution><institution>Kaohsiung Medical University, </institution></institution-wrap>Kaohsiung, Taiwan </aff><aff id="Aff8"><label>8</label>Division of Colorectal Surgery, Department of Surgery, Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan </aff><aff id="Aff9"><label>9</label>Colon and Rectal Surgery, Tainan Sin-Lau Hospital, Tainan, Taiwan </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0627 9786</institution-id><institution-id institution-id-type="GRID">grid.413535.5</institution-id><institution>Division of Hematology-Oncology, Department of Internal Medicine, </institution><institution>Cathay General Hospital, </institution></institution-wrap>Taipei, Taiwan </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9476 5696</institution-id><institution-id institution-id-type="GRID">grid.412019.f</institution-id><institution></institution><institution>Center for Biomarkers and Biotech Drugs, Kaohsiung Medical University, </institution></institution-wrap>Kaohsiung, Taiwan </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9476 5696</institution-id><institution-id institution-id-type="GRID">grid.412019.f</institution-id><institution>Research Center for Environmental Medicine, College of Medicine, </institution><institution>Kaohsiung Medical University, </institution></institution-wrap>Kaohsiung, Taiwan </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9476 5696</institution-id><institution-id institution-id-type="GRID">grid.412019.f</institution-id><institution>Research Center for Natural Products and Drug Development, </institution><institution>Kaohsiung Medical University, </institution></institution-wrap>Kaohsiung, Taiwan </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9476 5696</institution-id><institution-id institution-id-type="GRID">grid.412019.f</institution-id><institution></institution><institution>Division of Colorectal surgery, Department of Surgery, Faculty of Medicine, College of Medicine, </institution></institution-wrap>No. 100 Tzyou 1st Road, San-Ming District, Kaohsiung, 807 Taiwan </aff><aff id="Aff15"><label>15</label>Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, No. 100 Tzyou 1st Road, San-Ming District, Kaohsiung, 807 Taiwan </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>4</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>4</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>18</volume><elocation-id>191</elocation-id><history><date date-type="received"><day>24</day><month>8</month><year>2016</year></date><date date-type="accepted"><day>14</day><month>3</month><year>2017</year></date></history><permissions><copyright-statement>© The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title><offsets xml_i="9097" xml_f="9107" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="9118" xml_f="9470" txt_i="22" txt_f="374">We conducted a prospective randomized study of an adjuvant oxaliplatin-based regimen plus orally administered tegafur-uracil in patients with stage III colon cancer after radical resection to evaluate the feasibility of this drug combination in cancer clinical outcomes, acute toxicity, disease-free survival (DFS), and overall survival (OS) in Taiwan.</offsets></p></sec><sec><title><offsets xml_i="9492" xml_f="9506" txt_i="376" txt_f="390">Methods/design</offsets></title><p><offsets xml_i="9517" xml_f="10538" txt_i="391" txt_f="1412">This is an open-label, randomized, comparative, double-arm, multicenter, phase III study to assess DFS, OS, and safety profiles of the aforementioned drug combination as maintenance therapy for 1 year in patients with stage III colon cancer after radical resection in Taiwan. Following the completion of an adjuvant oxaliplatin-based regimen for 3 weeks with no evident disease recurrence, all eligible patients will be randomly assigned to either arm A (maintenance therapy) or arm B (observation arm) in a 2:1 ratio (364 and 182 patients in the tegafur-uracil and observation groups, respectively). Treatment in arm A will be started within 7 days of randomization. If the patients reported disease recurrence, intolerable toxicity, withdrew consent or the investigator determined that the patient should be withdrawn during the study period, they were withdrawn from the study. If a patient was discontinued from the study, the corresponding data were not reused, and the patient was not allowed to re-enter the study.</offsets></p></sec><sec><title><offsets xml_i="10560" xml_f="10570" txt_i="1414" txt_f="1424">Discussion</offsets></title><p><offsets xml_i="10581" xml_f="10845" txt_i="1425" txt_f="1689">A unique characteristic of this intervention was that the adjuvant chemotherapy with oxaliplatin and tegafur-uracil was anticipated to be safe and has high treatment efficacy, with the advantage of yielding a favorable response rate and tolerable toxicity profile.</offsets></p></sec><sec><title><offsets xml_i="10867" xml_f="10885" txt_i="1691" txt_f="1709">Trial registration</offsets></title><p><offsets xml_i="10896" xml_f="10928" txt_i="1710" txt_f="1742">ClinicalTrials.gov, identifier: </offsets><ext-link ext-link-type="uri" xlink:href="https://register.clinicaltrials.gov/prs/app/action/SelectProtocol?sid=S0006BX6&amp;selectaction=Edit&amp;uid=U00023LB&amp;ts=2&amp;cx=-ayipmh"><offsets xml_i="11113" xml_f="11124" txt_i="1742" txt_f="1753">NCT02836977</offsets></ext-link><offsets xml_i="11135" xml_f="11165" txt_i="1753" txt_f="1783">. Registered on 18 July 2016. </offsets></p></sec><sec><title><offsets xml_i="11187" xml_f="11220" txt_i="1785" txt_f="1818">Electronic supplementary material</offsets></title><p><offsets xml_i="11231" xml_f="11370" txt_i="1819" txt_f="1958">The online version of this article (doi:10.1186/s13063-017-1904-9) contains supplementary material, which is available to authorized users.</offsets></p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Tegafur-uracil</kwd><kwd>Oxaliplatin</kwd><kwd>Stage III colon cancer</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title><offsets xml_i="11741" xml_f="11751" txt_i="1967" txt_f="1977">Background</offsets></title><sec id="Sec2"><title><offsets xml_i="11781" xml_f="11793" txt_i="1978" txt_f="1990">Epidemiology</offsets></title><p><offsets xml_i="11804" xml_f="12321" txt_i="1991" txt_f="2505">Colorectal cancer (CRC), the most frequently diagnosed cancer, is the third leading cause of cancer-related deaths in Taiwan. During the past decade, the incidence rate of CRC has increased from 38 to 70 per 100,000 men and 30 to 51 per 100,000 women. The annual incidence of CRC in Taiwan has increased up to 43.5% in the past decade, with more than 15,000 new cases and &gt;5000 deaths annually; among these patients, approximately one fourth had stage III disease according to the Taiwan Cancer Registry Database [</offsets><xref ref-type="bibr" rid="CR1"><offsets xml_i="12353" xml_f="12354" txt_i="2505" txt_f="2506">1</offsets></xref><offsets xml_i="12361" xml_f="12363" txt_i="2506" txt_f="2508">, </offsets><xref ref-type="bibr" rid="CR2"><offsets xml_i="12395" xml_f="12396" txt_i="2508" txt_f="2509">2</offsets></xref><offsets xml_i="12403" xml_f="12637" txt_i="2509" txt_f="2743">]. Approximately 42% of stage III colon cancer cases have recurrences within 8 years after radical resection. In the 8-year follow-up period, 82% of patients with stage III colon cancer experienced recurrences in the initial 3 years [</offsets><xref ref-type="bibr" rid="CR3"><offsets xml_i="12669" xml_f="12670" txt_i="2743" txt_f="2744">3</offsets></xref><offsets xml_i="12677" xml_f="12679" txt_i="2744" txt_f="2746">].</offsets></p></sec><sec id="Sec3"><title><offsets xml_i="12711" xml_f="12737" txt_i="2748" txt_f="2774">Current treatment modality</offsets></title><p><offsets xml_i="12748" xml_f="12885" txt_i="2775" txt_f="2912">Intravenously administered (IV) 5-fluorouracil (FU) has been the most widely used chemotherapeutic agent for CRC for more than 40 years [</offsets><xref ref-type="bibr" rid="CR4"><offsets xml_i="12917" xml_f="12918" txt_i="2912" txt_f="2913">4</offsets></xref><offsets xml_i="12925" xml_f="13092" txt_i="2913" txt_f="3080">] and is included in various combination treatments such as those with oxaliplatin and irinotecan with or without biological agents (i.e., cetuximab and bevacizumab) [</offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="13124" xml_f="13125" txt_i="3080" txt_f="3081">5</offsets></xref><offsets xml_i="13132" xml_f="13163" txt_i="3081" txt_f="3112">]. Since 2004, FOLFOX4 (85 mg/m</offsets><sup><offsets xml_i="13168" xml_f="13169" txt_i="3112" txt_f="3113">2</offsets></sup><offsets xml_i="13175" xml_f="13210" txt_i="3113" txt_f="3148"> oxaliplatin combined with 200 mg/m</offsets><sup><offsets xml_i="13215" xml_f="13216" txt_i="3148" txt_f="3149">2</offsets></sup><offsets xml_i="13222" xml_f="13271" txt_i="3149" txt_f="3198"> leucovorin (LV) over 2 h, followed by a 400-mg/m</offsets><sup><offsets xml_i="13276" xml_f="13277" txt_i="3198" txt_f="3199">2</offsets></sup><offsets xml_i="13283" xml_f="13335" txt_i="3199" txt_f="3251"> 5-FU bolus and 22-h continuous infusion of 600 mg/m</offsets><sup><offsets xml_i="13340" xml_f="13341" txt_i="3251" txt_f="3252">2</offsets></sup><offsets xml_i="13347" xml_f="13412" txt_i="3252" txt_f="3317"> 5-FU) has been the accepted first-line therapy in advanced CRC [</offsets><xref ref-type="bibr" rid="CR6"><offsets xml_i="13444" xml_f="13445" txt_i="3317" txt_f="3318">6</offsets></xref><offsets xml_i="13452" xml_f="13493" txt_i="3318" txt_f="3359">]. The FOLFOX6 regimen comprises 100 mg/m</offsets><sup><offsets xml_i="13498" xml_f="13499" txt_i="3359" txt_f="3360">2</offsets></sup><offsets xml_i="13505" xml_f="13530" txt_i="3360" txt_f="3385"> oxaliplatin and 400 mg/m</offsets><sup><offsets xml_i="13535" xml_f="13536" txt_i="3385" txt_f="3386">2</offsets></sup><offsets xml_i="13542" xml_f="13596" txt_i="3386" txt_f="3440"> LV as a 2-h infusion on day l, followed by a 400-mg/m</offsets><sup><offsets xml_i="13601" xml_f="13602" txt_i="3440" txt_f="3441">2</offsets></sup><offsets xml_i="13608" xml_f="13671" txt_i="3441" txt_f="3504"> 5-FU IV bolus and a 46-h continuous infusion of 2400–3000 mg/m</offsets><sup><offsets xml_i="13676" xml_f="13677" txt_i="3504" txt_f="3505">2</offsets></sup><offsets xml_i="13683" xml_f="13736" txt_i="3505" txt_f="3558"> 5-FU; this regimen was repeated at 2-week intervals.</offsets></p></sec><sec id="Sec4"><title><offsets xml_i="13768" xml_f="13808" txt_i="3560" txt_f="3600">Investigational product (IP) description</offsets></title><p><offsets xml_i="13819" xml_f="14487" txt_i="3601" txt_f="4269">Tegafur-uracil, containing tegafur and uracil in a molar ratio of 1:4, is an antimalignant tumor agent with an antimetabolic effect. Tegafur is metabolized in vivo to 5-FU, which is a pyrimidine analog antimetabolite that is metabolized to 5-fluoro-2’-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP inhibits deoxyribonucleic acid (DNA) synthesis by binding to thymidylate synthase and inhibiting thymidylate production. FUTP interferes with ribonucleic acid (RNA) processing when it is mistakenly incorporated instead of uridine triphosphate. Uracil facilitates maintaining intracellular levels of 5-FU by inhibiting its degradation.</offsets></p><p><offsets xml_i="14494" xml_f="14789" txt_i="4270" txt_f="4565">Clinical trials have confirmed that the optimal combination ratio of tegafur-uracil yields long-lasting characteristics and high 5-FU concentrations in tumors. They have revealed the efficacy of tegafur-uracil as an antitumor agent for treating head and neck, gastric and breast cancers and CRC.</offsets></p></sec><sec id="Sec5"><title><offsets xml_i="14821" xml_f="14837" txt_i="4567" txt_f="4583">Preclinical data</offsets></title><p><offsets xml_i="14848" xml_f="15337" txt_i="4584" txt_f="5073">Tegafur-uracil can inhibit the growth of tumors such as Walker 256 carcinosarcoma, Yoshida sarcoma, ascites carcinoma (in rats), sarcoma 180, Ehrlich carcinoma, Lewis lung carcinoma, and B-16 melanoma (in mice) transplanted subcutaneously. It can also inhibit the growth of human cancers, such as gastric, beast, and pancreatic cancers, when transplanted subcutaneously in nude mice. In addition, its survival effects have been proven in animals (mice) bearing L1210 transplanted leukemia.</offsets></p><p><offsets xml_i="15344" xml_f="15791" txt_i="5074" txt_f="5521">The antitumor activity of tegafur-uracil is based on 5-FU that appears gradually in the body through the transformation of tegafur. The mechanism of 5-FU is considered to be the inhibition of DNA synthesis, resulting from the antagonistic effect of the active metabolite FdUMP on dUMP to inhibit thymidylate synthase, and RNA-function disorders, resulting from the incorporation of FUTP into RNA. Uracil enhances the antitumor activity of tegafur.</offsets></p></sec><sec id="Sec6"><title><offsets xml_i="15823" xml_f="15851" txt_i="5523" txt_f="5551">Clinical data and experience</offsets></title><p><offsets xml_i="15862" xml_f="16041" txt_i="5552" txt_f="5731">The efficacy of adjuvant treatment in CRC was clearly demonstrated as recently as the early 1990s, and 5-FU + LV became the standard treatment for stage III colon cancer in 1996 [</offsets><xref ref-type="bibr" rid="CR7"><offsets xml_i="16073" xml_f="16074" txt_i="5731" txt_f="5732">7</offsets></xref><offsets xml_i="16081" xml_f="16083" txt_i="5732" txt_f="5734">, </offsets><xref ref-type="bibr" rid="CR8"><offsets xml_i="16115" xml_f="16116" txt_i="5734" txt_f="5735">8</offsets></xref><offsets xml_i="16123" xml_f="16144" txt_i="5735" txt_f="5756">]. The MOSAIC trial [</offsets><xref ref-type="bibr" rid="CR9"><offsets xml_i="16176" xml_f="16177" txt_i="5756" txt_f="5757">9</offsets></xref><offsets xml_i="16184" xml_f="16341" txt_i="5757" txt_f="5914">] demonstrated the superiority of FOLFOX4 over 5-FU + LV, and in 2004, the FOLFOX4 regimen became the standard adjuvant treatment for stage III colon cancer.</offsets></p><p><offsets xml_i="16348" xml_f="16837" txt_i="5915" txt_f="6404">Several clinical trials have demonstrated the efficacy of tegafur-uracil in postoperative adjuvant chemotherapy. The basic data from these studies indicate a possible contribution of the antiangiogenic activity of tegafur-uracil to its overall antitumor activity, which until now has been considered to be mediated by the cytotoxic effects of 5-FU. Thus, tegafur-uracil seems to be particularly useful in a chronic postoperative adjuvant chemotherapy regimen to prevent cancer progression.</offsets></p><p><offsets xml_i="16844" xml_f="17405" txt_i="6405" txt_f="6966">Each cycle of tegafur-uracil + LV reduced the mean clinical visits by 66%, house staff visits by 17%, health professional visits by 36%, transfusion procedures by 74%, and diagnostic procedures by 33% compared with 5-FU + LV. In addition, tegafur-uracil + LV reduced monthly clinical visits of each patient by 4.5 h compared with 5-FU + LV. Tegafur-uracil + LV was associated with lower resource use than was an 5-FU + LV IV bolus, mainly because of fewer hospitalizations for the treatment of adverse events (AEs; tegafur-uracil + LV (21%) versus 5-FU (36%)) [</offsets><xref ref-type="bibr" rid="CR10"><offsets xml_i="17438" xml_f="17440" txt_i="6966" txt_f="6968">10</offsets></xref><offsets xml_i="17447" xml_f="17449" txt_i="6968" txt_f="6970">].</offsets></p></sec><sec id="Sec7"><title><offsets xml_i="17481" xml_f="17496" txt_i="6972" txt_f="6987">Trial rationale</offsets></title><p><offsets xml_i="17507" xml_f="17676" txt_i="6988" txt_f="7157">Additional maintenance therapy (12 cycles of tegafur-uracil (400 mg daily) + LV ((60 mg daily) for 28 days at a 7-day interval), followed by six cycles of 5-FU (375 mg/m</offsets><sup><offsets xml_i="17681" xml_f="17682" txt_i="7157" txt_f="7158">2</offsets></sup><offsets xml_i="17688" xml_f="17900" txt_i="7158" txt_f="7370">) + LV (30 mg daily) by a rapid IV injection for 5 days every 4 weeks (the Mayo Clinic regimen) significantly enhanced disease-free survival (DFS) compared with 5-FU + LV in patients with stage III colon cancer [</offsets><xref ref-type="bibr" rid="CR11"><offsets xml_i="17933" xml_f="17935" txt_i="7370" txt_f="7372">11</offsets></xref><offsets xml_i="17942" xml_f="18605" txt_i="7372" txt_f="8035">]. In patients with advanced CRC, a sequential therapy with a highly active chemotherapeutic regimen (e.g., FOLFOX4) for 6 months, followed by maintenance therapy with orally administered fluoropyrimidine (e.g., tegafur-uracil) is advantageous for obtaining a favorable toxicity profile and ease of administration by the oral route which is preferable for patients because of the more convenient outpatient therapy. The maintenance therapy with oral tegafur-uracil for patients responding to FOLFOX4 can maintain the treatment response and improve quality of life because it allows an outpatient regimen and the oral therapy entails lower psychological distress [</offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="18637" xml_f="18638" txt_i="8035" txt_f="8036">5</offsets></xref><offsets xml_i="18645" xml_f="18647" txt_i="8036" txt_f="8038">].</offsets></p><p><offsets xml_i="18654" xml_f="18914" txt_i="8039" txt_f="8299">Adjuvant chemotherapy may prolong the 3-year DFS in patients with stage III colon cancer. However, cold-triggered, acute sensory reversible neuropathy and treatment-limiting chronic sensory neurotoxicity are associated with the cumulative dose of oxaliplatin [</offsets><xref ref-type="bibr" rid="CR12"><offsets xml_i="18947" xml_f="18949" txt_i="8299" txt_f="8301">12</offsets></xref><offsets xml_i="18956" xml_f="19353" txt_i="8301" txt_f="8698">], which is an indication to stop oxaliplatin treatment in patients who are still responding to treatment. Therefore, we designed a trial to demonstrate the utility of maintenance therapy with tegafur-uracil in patients with stage III colon cancer after a 6-month oxaliplatin-based regimen. The primary objective of this trial was to verify the 3-year DFS after 1 year of tegafur-uracil treatment.</offsets></p></sec></sec><sec id="Sec8"><title><offsets xml_i="19391" xml_f="19400" txt_i="8701" txt_f="8710">Objective</offsets></title><sec id="Sec9"><title><offsets xml_i="19430" xml_f="19447" txt_i="8711" txt_f="8728">Primary objective</offsets></title><p><offsets xml_i="19458" xml_f="19665" txt_i="8729" txt_f="8936">To compare the 3-year DFS of tegafur-uracil following an adjuvant oxaliplatin-based regimen with that of an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection.</offsets></p></sec><sec id="Sec10"><title><offsets xml_i="19698" xml_f="19718" txt_i="8938" txt_f="8958">Secondary objectives</offsets></title><p><offsets xml_i="19729" xml_f="19730" txt_i="8959" txt_f="8960">
</offsets><list list-type="order"><list-item><p><offsets xml_i="19768" xml_f="19866" txt_i="8960" txt_f="9058">To assess and compare the 5-year overall survival (OS) in maintenance therapy and observation arms</offsets></p></list-item><list-item><p><offsets xml_i="19896" xml_f="19950" txt_i="9059" txt_f="9113">To assess and compare the safety profiles in both arms</offsets></p></list-item></list><offsets xml_i="19973" xml_f="19974" txt_i="9114" txt_f="9115">
</offsets></p></sec></sec><sec id="Sec11"><title><offsets xml_i="20013" xml_f="20027" txt_i="9118" txt_f="9132">Methods/design</offsets></title><p><offsets xml_i="20038" xml_f="20090" txt_i="9133" txt_f="9185">We will recruit participants from following centers:</offsets></p><p><offsets xml_i="20097" xml_f="20482" txt_i="9186" txt_f="9571">Kaohsiung Medical University Hospital (IRB number: KMUHIRB-F(I)-20160016), Cathay General Hospital, Taipei Medical University Hospital, Far Eastern Memorial Hospital, Tri-Service General Hospital, Taichung Veterans General Hospital, China Medical University Hospital, Chung Shan Medical University Hospital, Kaohsiung Veterans General Hospital, National Cheng Kung University Hospital.</offsets></p></sec><sec id="Sec12"><title><offsets xml_i="20515" xml_f="20547" txt_i="9573" txt_f="9605">Patient selection and enrollment</offsets></title><sec id="Sec13"><title><offsets xml_i="20578" xml_f="20592" txt_i="9606" txt_f="9620">Patient number</offsets></title><p><offsets xml_i="20603" xml_f="21015" txt_i="9621" txt_f="10033">Eligible patients will be randomized in two arms in a ratio of 2:1 to reach an approximate total of 546 patients. The sample size ratio is 2:1 (study arm is 2, control is 1), treatment duration is 1 year. Based on data of the 3-year DFS rate from our previous retrospective study, the proportion of control arm is 0.55 (55%) and of the study arm is 0.7 (70%) with a significance level of 0.05 and a power of 80%.</offsets></p></sec><sec id="Sec14"><title><offsets xml_i="21048" xml_f="21066" txt_i="10035" txt_f="10053">Inclusion criteria</offsets></title><p><offsets xml_i="21077" xml_f="21154" txt_i="10054" txt_f="10131">For inclusion in the study, each patient must fulfill the following criteria:</offsets><list list-type="order"><list-item><p><offsets xml_i="21192" xml_f="21227" txt_i="10131" txt_f="10166">Pathology-confirmed colon carcinoma</offsets></p></list-item><list-item><p><offsets xml_i="21257" xml_f="21277" txt_i="10167" txt_f="10187">Stage III disease (T</offsets><sub><offsets xml_i="21282" xml_f="21285" txt_i="10187" txt_f="10190">1–4</offsets></sub><offsets xml_i="21291" xml_f="21294" txt_i="10190" txt_f="10193">, N</offsets><sub><offsets xml_i="21299" xml_f="21302" txt_i="10193" txt_f="10196">1–2</offsets></sub><offsets xml_i="21308" xml_f="21315" txt_i="10196" txt_f="10203">, and M</offsets><sub><offsets xml_i="21320" xml_f="21321" txt_i="10203" txt_f="10204">0</offsets></sub><offsets xml_i="21327" xml_f="21401" txt_i="10204" txt_f="10278">, as defined by the American Joint Committee on Cancer (AJCC) 7th edition)</offsets></p></list-item><list-item><p><offsets xml_i="21431" xml_f="21518" txt_i="10279" txt_f="10366">Completion of an adjuvant oxaliplatin-based regimen, with no evident disease recurrence</offsets></p></list-item><list-item><p><offsets xml_i="21548" xml_f="21622" txt_i="10367" txt_f="10441">Entry in the trial within 3 weeks of an adjuvant oxaliplatin-based regimen</offsets></p></list-item><list-item><p><offsets xml_i="21652" xml_f="21707" txt_i="10442" txt_f="10497">Eastern Cooperative Oncology Group (ECOG) status of 0–2</offsets></p></list-item><list-item><p><offsets xml_i="21737" xml_f="21753" txt_i="10498" txt_f="10514">Aged 20–80 years</offsets></p></list-item><list-item><p><offsets xml_i="21783" xml_f="21844" txt_i="10515" txt_f="10576">Written informed consent provided to participate in the trial</offsets></p></list-item></list><offsets xml_i="21867" xml_f="21868" txt_i="10577" txt_f="10578">
</offsets></p></sec><sec id="Sec15"><title><offsets xml_i="21901" xml_f="21919" txt_i="10580" txt_f="10598">Exclusion criteria</offsets></title><p><offsets xml_i="21930" xml_f="22012" txt_i="10599" txt_f="10681">Patients fulfilling any of the following criteria will be excluded from the trial:</offsets><list list-type="alpha-lower"><list-item><p><offsets xml_i="22056" xml_f="22222" txt_i="10681" txt_f="10847">Previous or current systemic malignancy except curatively treated nonmelanoma skin cancer or in situ cervical carcinoma, unless there exists a DFS of at least 5 years</offsets></p></list-item><list-item><p><offsets xml_i="22252" xml_f="22305" txt_i="10848" txt_f="10901">Inadequate hematopoietic function defined as follows:</offsets><list list-type="order"><list-item><p><offsets xml_i="22343" xml_f="22365" txt_i="10901" txt_f="10920">Hemoglobin &lt; 9 g/dL</offsets></p></list-item><list-item><p><offsets xml_i="22395" xml_f="22439" txt_i="10921" txt_f="10962">Absolute neutrophil count (ANC) &lt; 1500/mm</offsets><sup><offsets xml_i="22444" xml_f="22445" txt_i="10962" txt_f="10963">3</offsets></sup><offsets xml_i="22451" xml_f="22452" txt_i="10963" txt_f="10964">
</offsets></p></list-item><list-item><p><offsets xml_i="22482" xml_f="22512" txt_i="10965" txt_f="10992">Platelet count &lt; 100,000/mm</offsets><sup><offsets xml_i="22517" xml_f="22518" txt_i="10992" txt_f="10993">3</offsets></sup><offsets xml_i="22524" xml_f="22525" txt_i="10993" txt_f="10994">
</offsets></p></list-item></list><offsets xml_i="22548" xml_f="22549" txt_i="10995" txt_f="10996">
</offsets></p></list-item><list-item><p><offsets xml_i="22579" xml_f="22625" txt_i="10997" txt_f="11043">Inadequate organ functions defined as follows:</offsets><list list-type="order"><list-item><p><offsets xml_i="22663" xml_f="22722" txt_i="11043" txt_f="11099">Total bilirubin &gt;2 times the upper limit of normal (ULN)</offsets></p></list-item><list-item><p><offsets xml_i="22752" xml_f="22857" txt_i="11100" txt_f="11202">Hepatic transaminases (alanine aminotransferase (ALT) and aspartate aminotransferase (AST)) &gt;2.5 × ULN</offsets></p></list-item><list-item><p><offsets xml_i="22887" xml_f="22911" txt_i="11203" txt_f="11224">Creatinine &gt;1.5 × ULN</offsets></p></list-item></list><offsets xml_i="22934" xml_f="22935" txt_i="11225" txt_f="11226">
</offsets></p></list-item><list-item><p><offsets xml_i="22965" xml_f="23133" txt_i="11227" txt_f="11395">Other severe medical conditions that are contraindicated to tegafur-uracil or render patients at a high risk of treatment complications based on investigator discretion</offsets></p></list-item><list-item><p><offsets xml_i="23163" xml_f="23207" txt_i="11396" txt_f="11440">Presence of other severe concomitant illness</offsets></p></list-item><list-item><p><offsets xml_i="23237" xml_f="23348" txt_i="11441" txt_f="11552">Participation in another clinical trial with any investigational product (IP) within 30 days before study entry</offsets></p></list-item><list-item><p><offsets xml_i="23378" xml_f="23440" txt_i="11553" txt_f="11615">Pregnant or lactating women or women of childbearing potential</offsets></p></list-item></list><offsets xml_i="23463" xml_f="23464" txt_i="11616" txt_f="11617">
</offsets></p></sec><sec id="Sec16"><title><offsets xml_i="23497" xml_f="23527" txt_i="11619" txt_f="11649">Trial enrollment method (Fig. </offsets><xref rid="Fig1" ref-type="fig"><offsets xml_i="23559" xml_f="23560" txt_i="11649" txt_f="11650">1</offsets></xref><offsets xml_i="23567" xml_f="23575" txt_i="11650" txt_f="11658">,  Fig. </offsets><xref rid="Fig2" ref-type="fig"><offsets xml_i="23607" xml_f="23608" txt_i="11658" txt_f="11659">2</offsets></xref><offsets xml_i="23615" xml_f="23616" txt_i="11659" txt_f="11660">)</offsets></title><p><offsets xml_i="23627" xml_f="23628" txt_i="11661" txt_f="11662">
</offsets><fig id="Fig1"><label><offsets xml_i="23650" xml_f="23656" txt_i="11662" txt_f="11668">Fig. 1</offsets></label><caption><p><offsets xml_i="23676" xml_f="23714" txt_i="11668" txt_f="11706">Trial enrollment. Stage III disease: T</offsets><sub><offsets xml_i="23719" xml_f="23722" txt_i="11706" txt_f="11709">1–4</offsets></sub><offsets xml_i="23728" xml_f="23731" txt_i="11709" txt_f="11712">, N</offsets><sub><offsets xml_i="23736" xml_f="23739" txt_i="11712" txt_f="11715">1–2</offsets></sub><offsets xml_i="23745" xml_f="23752" txt_i="11715" txt_f="11722">, and M</offsets><sub><offsets xml_i="23757" xml_f="23758" txt_i="11722" txt_f="11723">0</offsets></sub><offsets xml_i="23764" xml_f="24010" txt_i="11723" txt_f="11969">, as defined by the AJCC 7th edition. Completion of an adjuvant oxaliplatin-based regimen with no evident disease recurrence. The patients were withdrawn in cases of disease recurrence, intolerable toxicity, or consent withdrawal during the study</offsets></p></caption><graphic xlink:href="13063_2017_1904_Fig1_HTML" id="MO1"></graphic></fig><offsets xml_i="24097" xml_f="24098" txt_i="11970" txt_f="11971">
</offsets><fig id="Fig2"><label><offsets xml_i="24120" xml_f="24126" txt_i="11971" txt_f="11977">Fig. 2</offsets></label><caption><p><offsets xml_i="24146" xml_f="24193" txt_i="11977" txt_f="12024">Flowsheet for pre/post-treatment investigations</offsets></p></caption><graphic xlink:href="13063_2017_1904_Fig2_HTML" id="MO2"></graphic></fig><offsets xml_i="24280" xml_f="24281" txt_i="12025" txt_f="12026">
</offsets></p><p><offsets xml_i="24288" xml_f="24365" txt_i="12027" txt_f="12104">Patient eligibility criteria will be established before treatment enrollment.</offsets></p><p><offsets xml_i="24372" xml_f="24770" txt_i="12105" txt_f="12503">Following the completion of an adjuvant oxaliplatin-based regimen within 3 weeks with no evident disease recurrence, all eligible patients will be randomly assigned to either arm A (maintenance therapy) or arm B (observation arm) in a 2:1 ratio (364 and 182 patients in the tegafur-uracil and observation groups, respectively). Treatment in arm A will be started within 7 days of the randomization.</offsets></p><p><offsets xml_i="24777" xml_f="25133" txt_i="12504" txt_f="12860">If the patients report disease recurrence, intolerable toxicity, or consent withdrawal or are removed according to the investigator’s discretion during the study period, they will be withdrawn from the study. If a patient wishes to discontinue the study, the corresponding data will not be reused, and the patient will not be allowed to re-enter the study.</offsets></p></sec></sec><sec id="Sec17"><title><offsets xml_i="25172" xml_f="25182" txt_i="12863" txt_f="12873">Study plan</offsets></title><sec id="Sec18"><title><offsets xml_i="25213" xml_f="25225" txt_i="12874" txt_f="12886">Study design</offsets></title><p><offsets xml_i="25236" xml_f="25561" txt_i="12887" txt_f="13212">This is an open-label, randomized, comparative, double-arm, multicenter, phase III study to assess DFS, OS, and safety profiles with tegafur-uracil following an adjuvant oxaliplatin-based regimen as maintenance therapy for 1 year in patients with stage III colon cancer after radical resection in Taiwan (see Additional file </offsets><xref rid="MOESM1" ref-type="media"><offsets xml_i="25597" xml_f="25598" txt_i="13212" txt_f="13213">1</offsets></xref><offsets xml_i="25605" xml_f="25637" txt_i="13213" txt_f="13245"> for the SPIRIT 2013 checklist).</offsets></p></sec><sec id="Sec19"><title><offsets xml_i="25670" xml_f="25684" txt_i="13247" txt_f="13261">Patient number</offsets></title><p><offsets xml_i="25695" xml_f="25805" txt_i="13262" txt_f="13372">Eligible patients will be randomized in two arms in a 2:1 ratio to reach an approximate total of 546 patients.</offsets></p></sec><sec id="Sec20"><title><offsets xml_i="25838" xml_f="25852" txt_i="13374" txt_f="13388">Study schedule</offsets></title><p><offsets xml_i="25863" xml_f="25984" txt_i="13389" txt_f="13510">Study date: the time of obtaining an approval letter from both regulatory authority and Institutional Review Board (IRB).</offsets><list list-type="bullet"><list-item><p><offsets xml_i="26023" xml_f="26067" txt_i="13510" txt_f="13554">Expected recruitment rate: 24 patients/month</offsets></p></list-item><list-item><p><offsets xml_i="26097" xml_f="26131" txt_i="13555" txt_f="13589">Recruitment date: at least 2 years</offsets></p></list-item><list-item><p><offsets xml_i="26161" xml_f="26193" txt_i="13590" txt_f="13622">Study duration: at least 5 years</offsets></p></list-item></list><offsets xml_i="26216" xml_f="26217" txt_i="13623" txt_f="13624">
</offsets></p></sec><sec id="Sec21"><title><offsets xml_i="26250" xml_f="26264" txt_i="13626" txt_f="13640">Visit schedule</offsets></title><p><offsets xml_i="26275" xml_f="26309" txt_i="13641" txt_f="13675">The schedule of assessments (see ‘</offsets><xref rid="Sec35" ref-type="sec"><offsets xml_i="26342" xml_f="26361" txt_i="13675" txt_f="13694">Assessment schedule</offsets></xref><offsets xml_i="26368" xml_f="26551" txt_i="13694" txt_f="13877">’ below for details) indicates the number and timing of the planned visits, which must be followed as accurately as possible. Moreover, the visit schedule must be accurately followed.</offsets></p></sec><sec id="Sec22"><title><offsets xml_i="26584" xml_f="26602" txt_i="13879" txt_f="13897">Treatment duration</offsets></title><p><offsets xml_i="26613" xml_f="26804" txt_i="13898" txt_f="14089">Treatment will be administered for up to a maximum of 1 year, and in case of disease progression, intolerable toxicity, or consent withdrawal during the study, the patients will be withdrawn.</offsets></p></sec></sec><sec id="Sec23"><title><offsets xml_i="26843" xml_f="26858" txt_i="14092" txt_f="14107">Trial treatment</offsets></title><sec id="Sec24"><title><offsets xml_i="26889" xml_f="26928" txt_i="14108" txt_f="14147">Data on investigational product (Table </offsets><xref rid="Tab1" ref-type="table"><offsets xml_i="26962" xml_f="26963" txt_i="14147" txt_f="14148">1</offsets></xref><offsets xml_i="26970" xml_f="26971" txt_i="14148" txt_f="14149">)</offsets></title><p><offsets xml_i="26982" xml_f="26983" txt_i="14150" txt_f="14151">
</offsets><table-wrap id="Tab1"><label><offsets xml_i="27012" xml_f="27019" txt_i="14151" txt_f="14158">Table 1</offsets></label><caption><p><offsets xml_i="27039" xml_f="27074" txt_i="14158" txt_f="14193">Data on the investigational product</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th><offsets xml_i="27140" xml_f="27166" txt_i="14194" txt_f="14220">Name of active ingredients</offsets></th><th><offsets xml_i="27175" xml_f="27182" txt_i="14220" txt_f="14227">Tegafur</offsets></th><th><offsets xml_i="27191" xml_f="27197" txt_i="14227" txt_f="14233">Uracil</offsets></th></tr></thead><tbody><tr><td><offsets xml_i="27230" xml_f="27241" txt_i="14233" txt_f="14244">Description</offsets></td><td><offsets xml_i="27250" xml_f="27419" txt_i="14245" txt_f="14414">Tegafur occurs as a white crystalline powder. It is soluble in methanol, sparingly in water and ethanol, and slightly in ether. It is soluble in dilute sodium hydroxide.</offsets></td><td><offsets xml_i="27428" xml_f="27637" txt_i="14415" txt_f="14624">Uracil occurs as a white crystal or crystalline powder, free of odor or taste. It is slightly soluble in water; slightly soluble in methanol, ethanol and acetone; and insoluble in ethyl acetate and chloroform.</offsets></td></tr><tr><td><offsets xml_i="27655" xml_f="27664" txt_i="14625" txt_f="14634">Structure</offsets></td><td><offsets xml_i="27673" xml_f="27674" txt_i="14635" txt_f="14636">
</offsets><inline-graphic xlink:href="13063_2017_1904_Figa_HTML.gif" id="d29e1107"></inline-graphic><offsets xml_i="27764" xml_f="27765" txt_i="14636" txt_f="14637">
</offsets></td><td><offsets xml_i="27774" xml_f="27775" txt_i="14638" txt_f="14639">
</offsets><inline-graphic xlink:href="13063_2017_1904_Figb_HTML.gif" id="d29e1113"></inline-graphic><offsets xml_i="27865" xml_f="27866" txt_i="14639" txt_f="14640">
</offsets></td></tr><tr><td><offsets xml_i="27884" xml_f="27897" txt_i="14641" txt_f="14654">Chemical name</offsets></td><td><offsets xml_i="27906" xml_f="28009" txt_i="14655" txt_f="14758">1-(2-tetrahydrofuryl)-5-fluorouracid 5-fluoro-1-(2-tetrahydrofuryl)-2,4 (1H,3H)-pyrimidinedione (IUPAC)</offsets></td><td><offsets xml_i="28018" xml_f="28044" txt_i="14759" txt_f="14785">2,4(1H,3H)-pyrimidinedione</offsets></td></tr><tr><td><offsets xml_i="28062" xml_f="28079" txt_i="14786" txt_f="14803">Molecular formula</offsets></td><td><offsets xml_i="28088" xml_f="28089" txt_i="14804" txt_f="14805">C</offsets><sub><offsets xml_i="28094" xml_f="28095" txt_i="14805" txt_f="14806">8</offsets></sub><offsets xml_i="28101" xml_f="28102" txt_i="14806" txt_f="14807">H</offsets><sub><offsets xml_i="28107" xml_f="28108" txt_i="14807" txt_f="14808">9</offsets></sub><offsets xml_i="28114" xml_f="28116" txt_i="14808" txt_f="14810">FN</offsets><sub><offsets xml_i="28121" xml_f="28122" txt_i="14810" txt_f="14811">2</offsets></sub><offsets xml_i="28128" xml_f="28129" txt_i="14811" txt_f="14812">O</offsets><sub><offsets xml_i="28134" xml_f="28135" txt_i="14812" txt_f="14813">3</offsets></sub><offsets xml_i="28141" xml_f="28142" txt_i="14813" txt_f="14814">
</offsets></td><td><offsets xml_i="28151" xml_f="28152" txt_i="14815" txt_f="14816">C</offsets><sub><offsets xml_i="28157" xml_f="28158" txt_i="14816" txt_f="14817">4</offsets></sub><offsets xml_i="28164" xml_f="28165" txt_i="14817" txt_f="14818">H</offsets><sub><offsets xml_i="28170" xml_f="28171" txt_i="14818" txt_f="14819">4</offsets></sub><offsets xml_i="28177" xml_f="28178" txt_i="14819" txt_f="14820">N</offsets><sub><offsets xml_i="28183" xml_f="28184" txt_i="14820" txt_f="14821">2</offsets></sub><offsets xml_i="28190" xml_f="28191" txt_i="14821" txt_f="14822">O</offsets><sub><offsets xml_i="28196" xml_f="28197" txt_i="14822" txt_f="14823">2</offsets></sub><offsets xml_i="28203" xml_f="28204" txt_i="14823" txt_f="14824">
</offsets></td></tr><tr><td><offsets xml_i="28222" xml_f="28238" txt_i="14825" txt_f="14841">Molecular weight</offsets></td><td><offsets xml_i="28247" xml_f="28253" txt_i="14842" txt_f="14848">200.17</offsets></td><td><offsets xml_i="28262" xml_f="28268" txt_i="14849" txt_f="14855">112.09</offsets></td></tr><tr><td><offsets xml_i="28286" xml_f="28299" txt_i="14856" txt_f="14869">Melting point</offsets></td><td><offsets xml_i="28308" xml_f="28321" txt_i="14870" txt_f="14883">166 °C–171 °C</offsets></td><td><offsets xml_i="28330" xml_f="28350" txt_i="14884" txt_f="14904">Approximately 335 °C</offsets></td></tr><tr><td><offsets xml_i="28368" xml_f="28376" txt_i="14905" txt_f="14913">Contents</offsets></td><td colspan="2"><offsets xml_i="28397" xml_f="28452" txt_i="14914" txt_f="14969">Each capsule contains 100 mg tegafur and 224 mg uracil.</offsets></td></tr><tr><td><offsets xml_i="28470" xml_f="28487" txt_i="14970" txt_f="14987">Storage condition</offsets></td><td colspan="2"><offsets xml_i="28508" xml_f="28519" txt_i="14988" txt_f="14999">Below 30 °C</offsets></td></tr></tbody></table></table-wrap><offsets xml_i="28558" xml_f="28559" txt_i="15000" txt_f="15001">
</offsets></p><sec id="Sec25"><title><offsets xml_i="28586" xml_f="28647" txt_i="15002" txt_f="15063">Preparation and administration of the investigational product</offsets></title><p><offsets xml_i="28658" xml_f="28868" txt_i="15064" txt_f="15274">Tegafur-uracil capsules (200 mg) will be administered twice daily (400 mg daily) at regular intervals. They will be administered whole and either 1 h before or after food consumption in the morning and evening.</offsets></p></sec></sec><sec id="Sec26"><title><offsets xml_i="28907" xml_f="28926" txt_i="15277" txt_f="15296">Labeling and supply</offsets></title><p><offsets xml_i="28937" xml_f="29100" txt_i="15297" txt_f="15460">Tegafur-uracil is commercially available and supplied by the investigator’s pharmacy. The batch numbers of the used drugs will be diligently obtained and recorded.</offsets></p></sec><sec id="Sec27"><title><offsets xml_i="29133" xml_f="29140" txt_i="15462" txt_f="15469">Storage</offsets></title><p><offsets xml_i="29151" xml_f="29288" txt_i="15470" txt_f="15607">The drugs will be stored at below 30 °C. Procedures for the appropriate handling and disposal of anticancer medications will be followed.</offsets></p></sec><sec id="Sec28"><title><offsets xml_i="29321" xml_f="29350" txt_i="15609" txt_f="15638">Dosage and treatment regimens</offsets></title><p><offsets xml_i="29361" xml_f="29586" txt_i="15639" txt_f="15864">Eligible patients will receive orally administered tegafur-uracil (400 mg daily; 100 mg/capsule, two capsules each time, twice daily) and folinic acid (30 mg daily; 15 mg/tablet, one tablet each time, twice daily) for 1 year.</offsets></p></sec><sec id="Sec29"><title><offsets xml_i="29619" xml_f="29636" txt_i="15866" txt_f="15883">Dose modification</offsets></title><p><offsets xml_i="29647" xml_f="29648" txt_i="15884" txt_f="15885">
</offsets><list list-type="bullet"><list-item><p><offsets xml_i="29687" xml_f="29893" txt_i="15885" txt_f="16091">The dose after the first treatment will be modified on the basis of the highest toxicity degree graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.03</offsets></p></list-item><list-item><p><offsets xml_i="29923" xml_f="30328" txt_i="16092" txt_f="16497">For toxicities that are considered by the investigator to be unlikely to become severe or life-threatening and that do not result in a delay or interruption of therapy (e.g., alopecia and altered taste), treatment will be continued at the same dosing without reduction or interruption. No dose reductions or interruptions are required for anemia because it can be satisfactorily controlled by transfusions</offsets></p></list-item><list-item><p><offsets xml_i="30358" xml_f="30501" txt_i="16498" txt_f="16641">For the patients experiencing treatment interruption because of AEs for more than 2 weeks, treatment discontinuation will be considered (Table </offsets><xref rid="Tab2" ref-type="table"><offsets xml_i="30535" xml_f="30536" txt_i="16641" txt_f="16642">2</offsets></xref><offsets xml_i="30543" xml_f="30544" txt_i="16642" txt_f="16643">)</offsets><table-wrap id="Tab2"><label><offsets xml_i="30573" xml_f="30580" txt_i="16643" txt_f="16650">Table 2</offsets></label><caption><p><offsets xml_i="30600" xml_f="30617" txt_i="16650" txt_f="16667">Dose modification</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th><offsets xml_i="30683" xml_f="30699" txt_i="16668" txt_f="16684">Toxicity (grade)</offsets></th><th><offsets xml_i="30708" xml_f="30725" txt_i="16684" txt_f="16701">Dose modification</offsets></th></tr></thead><tbody><tr><td><offsets xml_i="30758" xml_f="30773" txt_i="16701" txt_f="16713">ANC &lt;1000/mm</offsets><sup><offsets xml_i="30778" xml_f="30779" txt_i="16713" txt_f="16714">3</offsets></sup><offsets xml_i="30785" xml_f="30786" txt_i="16714" txt_f="16715">
</offsets></td><td><offsets xml_i="30795" xml_f="30839" txt_i="16716" txt_f="16760">Discontinue the treatment until ANC ≥1500/mm</offsets><sup><offsets xml_i="30844" xml_f="30845" txt_i="16760" txt_f="16761">3</offsets></sup><offsets xml_i="30851" xml_f="30892" txt_i="16761" txt_f="16802">; resume the treatment with the same dose</offsets></td></tr><tr><td><offsets xml_i="30910" xml_f="30933" txt_i="16803" txt_f="16823">Platelets &lt;50,000/mm</offsets><sup><offsets xml_i="30938" xml_f="30939" txt_i="16823" txt_f="16824">3</offsets></sup><offsets xml_i="30945" xml_f="30946" txt_i="16824" txt_f="16825">
</offsets></td><td><offsets xml_i="30955" xml_f="31008" txt_i="16826" txt_f="16879">Discontinue the treatment until platelets ≥100,000/mm</offsets><sup><offsets xml_i="31013" xml_f="31014" txt_i="16879" txt_f="16880">3</offsets></sup><offsets xml_i="31020" xml_f="31061" txt_i="16880" txt_f="16921">; resume the treatment with the same dose</offsets></td></tr><tr><td><offsets xml_i="31079" xml_f="31095" txt_i="16922" txt_f="16938">Other toxicities</offsets></td><td><offsets xml_i="31104" xml_f="31149" txt_i="16939" txt_f="16984">No dose modification or interruption required</offsets></td></tr><tr><td><offsets xml_i="31167" xml_f="31182" txt_i="16985" txt_f="17000"> Grades 1 and 2</offsets></td><td rowspan="2"><offsets xml_i="31203" xml_f="31292" txt_i="17001" txt_f="17090">Discontinue the treatment until returns to baseline; resume the treatment to 200 mg daily</offsets></td></tr><tr><td><offsets xml_i="31310" xml_f="31325" txt_i="17091" txt_f="17106"> Grades 3 and 4</offsets></td></tr></tbody></table></table-wrap><offsets xml_i="31364" xml_f="31365" txt_i="17107" txt_f="17108">
</offsets></p></list-item><list-item><p><offsets xml_i="31395" xml_f="31396" txt_i="17109" txt_f="17110">
</offsets><italic><offsets xml_i="31404" xml_f="31407" txt_i="17110" txt_f="17113">ANC</offsets></italic><offsets xml_i="31416" xml_f="31442" txt_i="17113" txt_f="17139"> absolute neutrophil count</offsets><list list-type="bullet"><list-item><p><offsets xml_i="31481" xml_f="31519" txt_i="17139" txt_f="17177">Discontinuation of study participation</offsets></p></list-item></list><offsets xml_i="31542" xml_f="31543" txt_i="17178" txt_f="17179">
</offsets></p></list-item></list><offsets xml_i="31566" xml_f="31567" txt_i="17180" txt_f="17181">
</offsets></p><p><list list-type="bullet"><list-item><p><offsets xml_i="31613" xml_f="31631" txt_i="17182" txt_f="17200">Disease recurrence</offsets></p></list-item><list-item><p><offsets xml_i="31661" xml_f="31681" txt_i="17201" txt_f="17221">Intolerable toxicity</offsets></p></list-item><list-item><p><offsets xml_i="31711" xml_f="31729" txt_i="17222" txt_f="17240">Consent withdrawal</offsets></p></list-item><list-item><p><offsets xml_i="31759" xml_f="31782" txt_i="17241" txt_f="17264">Investigator discretion</offsets></p></list-item></list><offsets xml_i="31805" xml_f="31806" txt_i="17265" txt_f="17266">
</offsets></p><p><offsets xml_i="31813" xml_f="31900" txt_i="17267" txt_f="17354">All information regarding the withdrawal will be recorded in the Case Report Form (CRF)</offsets></p></sec><sec id="Sec30"><title><offsets xml_i="31933" xml_f="31981" txt_i="17356" txt_f="17404">Prestudy, concomitant, and post-study treatments</offsets></title><p><offsets xml_i="31992" xml_f="31993" txt_i="17405" txt_f="17406">
</offsets><list list-type="order"><list-item><p><offsets xml_i="32031" xml_f="32052" txt_i="17406" txt_f="17427">Concomitant treatment</offsets></p><p><offsets xml_i="32059" xml_f="32173" txt_i="17428" txt_f="17542">The use of all concomitant medications and supportive therapies at baseline will be recorded throughout the study.</offsets></p></list-item><list-item><p><offsets xml_i="32203" xml_f="32223" txt_i="17543" txt_f="17563">Prohibited treatment</offsets><list list-type="bullet"><list-item><label></label><p><offsets xml_i="32277" xml_f="32297" txt_i="17563" txt_f="17583">Treatment for cancer</offsets></p></list-item><list-item><label></label><p><offsets xml_i="32342" xml_f="32594" txt_i="17584" txt_f="17836">Except for the assigned study treatment, no other treatments known to exert an anticancer effect can be used during the trial (e.g., other chemotherapies, hormonal therapy, immunotherapy, antibody therapy, radiotherapy, thermotherapy, surgery, and IPs)</offsets></p></list-item><list-item><label></label><p><offsets xml_i="32639" xml_f="32650" txt_i="17837" txt_f="17848">Flucytosine</offsets></p></list-item><list-item><label></label><p><offsets xml_i="32695" xml_f="32727" txt_i="17849" txt_f="17881">Radiotherapy for supportive care</offsets></p></list-item><list-item><label></label><p><offsets xml_i="32772" xml_f="32781" txt_i="17882" txt_f="17891">Other IPs</offsets></p></list-item></list><offsets xml_i="32804" xml_f="32805" txt_i="17892" txt_f="17893">
</offsets></p></list-item><list-item><p><offsets xml_i="32835" xml_f="32860" txt_i="17894" txt_f="17919">Treatment with precaution</offsets><list list-type="bullet"><list-item><label></label><p><offsets xml_i="32914" xml_f="32937" txt_i="17919" txt_f="17942">Coumarin anticoagulants</offsets></p></list-item><list-item><label></label><p><offsets xml_i="32982" xml_f="33190" txt_i="17943" txt_f="18151">The patients treated with coumadin anticoagulants, such as warfarin, and concomitantly with tegafur-uracil will be regularly monitored for alterations in prothrombin time or the international normalized ratio</offsets></p></list-item><list-item><label></label><p><offsets xml_i="33235" xml_f="33244" txt_i="18152" txt_f="18161">Phenytoin</offsets><list list-type="bullet"><list-item><label></label><p><offsets xml_i="33298" xml_f="33437" txt_i="18161" txt_f="18300">The patients taking phenytoin concomitantly with tegafur-uracil will be regularly monitored for an increased phenytoin plasma concentration</offsets></p></list-item></list><offsets xml_i="33460" xml_f="33461" txt_i="18301" txt_f="18302">
</offsets></p></list-item></list><offsets xml_i="33484" xml_f="33485" txt_i="18303" txt_f="18304">
</offsets></p></list-item></list><offsets xml_i="33508" xml_f="33509" txt_i="18305" txt_f="18306">
</offsets></p></sec></sec><sec id="Sec31"><title><offsets xml_i="33548" xml_f="33579" txt_i="18309" txt_f="18340">Study measurement and endpoints</offsets></title><sec id="Sec32"><title><offsets xml_i="33610" xml_f="33648" txt_i="18341" txt_f="18379">Screening and demographic measurements</offsets></title><p><offsets xml_i="33659" xml_f="33903" txt_i="18380" txt_f="18624">The assessment schedule is illustrated in the ‘Assessment schedule’ section below. Each patient must sign and date an informed consent form before undergoing any study specific procedure, unless the procedure is considered the standard of care.</offsets></p><p><offsets xml_i="33910" xml_f="34042" txt_i="18625" txt_f="18757">Screening procedures will be performed before the first treatment according to the assessment schedule within the required timeline.</offsets><list list-type="order"><list-item><p><offsets xml_i="34080" xml_f="34116" txt_i="18757" txt_f="18793">Demographic and past medical history</offsets></p><p><offsets xml_i="34123" xml_f="34303" txt_i="18794" txt_f="18974">A complete medical history will be obtained at the screening visit. The medical history will include demographic information as well as any information pertinent to a CRC diagnosis</offsets></p></list-item><list-item><p><offsets xml_i="34333" xml_f="34390" txt_i="18975" txt_f="19032">Physical examination, vital signs, and performance status</offsets></p><p><offsets xml_i="34397" xml_f="34593" txt_i="19033" txt_f="19229">Physical examination will be conducted, and vital signs and the performance status will be reported within 14 days before the first treatment and be repeated at every visit until study completion.</offsets></p><p><offsets xml_i="34600" xml_f="34727" txt_i="19230" txt_f="19357">The vital signs, including height, weight, blood pressure, and performance status, will be recorded according to the ECOG Scale</offsets></p></list-item><list-item><p><offsets xml_i="34757" xml_f="34792" txt_i="19358" txt_f="19393">Hematological and biochemical tests</offsets></p><p><offsets xml_i="34799" xml_f="35175" txt_i="19394" txt_f="19770">Hematological and biochemical tests will be performed within 14 days before the first treatment. If any required hematological or biochemical values do not meet the eligibility criteria, the tests will be repeated before enrollment. If the tests performed within 7 days before the first treatment fulfill the eligibility criteria, tests are not required on day 1 of treatment.</offsets></p><p><offsets xml_i="35182" xml_f="35411" txt_i="19771" txt_f="20000">The hematological test comprises complete blood count (CBC) and differentiation count (D/C). CBC includes hemoglobin, hematocrit, erythrocytes, leukocytes, neutrophils, and platelets; The D/C will be calculated to obtain the ANC.</offsets></p><p><offsets xml_i="35418" xml_f="35560" txt_i="20001" txt_f="20143">The biochemical test measures albumin, alkaline phosphatase, ALT, AST, bilirubin (total and direct), blood urea nitrogen (BUN), and creatinine</offsets></p></list-item><list-item><p><offsets xml_i="35590" xml_f="35614" txt_i="20144" txt_f="20168">Carcinoembryonic antigen</offsets></p><p><offsets xml_i="35621" xml_f="35806" txt_i="20169" txt_f="20354">Carcinoembryonic antigen (CEA) will be assessed every 3 months before the first treatment and will be repeated every 3 months in the first and second years and every 6 months thereafter</offsets></p></list-item><list-item><p><offsets xml_i="35836" xml_f="35885" txt_i="20355" txt_f="20404">Computed tomography or magnetic resonance imaging</offsets></p><p><offsets xml_i="35892" xml_f="36198" txt_i="20405" txt_f="20711">Computed tomography (CT) or magnetic resonance imaging (MRI) will be annually performed in the first 2 years or if disease recurrence is suspected. The acceptable window for scheduling the imaging studies is ±1 week. Subsequently, CT or MRI will be performed only on suspected disease recurrence thereafter</offsets></p></list-item><list-item><p><offsets xml_i="36228" xml_f="36242" txt_i="20712" txt_f="20726">Abdominal echo</offsets></p><p><offsets xml_i="36249" xml_f="36535" txt_i="20727" txt_f="21013">Abdominal echo will be performed every 6 months. However, its actual implementation will be based on clinical practice. The schedule of CT or MRI and abdominal echo are crossed over, and the typical interval is 6 months. CT or MRI is the main examination when the schedule is duplicated</offsets></p></list-item><list-item><p><offsets xml_i="36565" xml_f="36576" txt_i="21014" txt_f="21025">Chest X-ray</offsets></p><p><offsets xml_i="36583" xml_f="36621" txt_i="21026" txt_f="21064">Chest X-ray will be annually performed</offsets></p></list-item><list-item><p><offsets xml_i="36651" xml_f="36665" txt_i="21065" txt_f="21079">Adverse events</offsets></p><p><offsets xml_i="36672" xml_f="36741" txt_i="21080" txt_f="21149">AEs will be recorded from the first treatment to treatment completion</offsets></p></list-item></list><offsets xml_i="36764" xml_f="36765" txt_i="21150" txt_f="21151">
</offsets></p></sec><sec id="Sec33"><title><offsets xml_i="36798" xml_f="36833" txt_i="21153" txt_f="21188">Efficacy measurements and endpoints</offsets></title><p><offsets xml_i="36844" xml_f="37034" txt_i="21189" txt_f="21379">In this study, we set 3-year DFS and 5-year OS as the primary endpoints and the differences the difference in survival distributions between two groups were analyzed using the log-rank test.</offsets><list list-type="bullet"><list-item><p><offsets xml_i="37073" xml_f="37111" txt_i="21379" txt_f="21417">Three-year disease-free survival (DFS)</offsets></p><p><offsets xml_i="37118" xml_f="37752" txt_i="21418" txt_f="22052">CEA and CT or MRI scan will be performed within 28 days before the treatment. The CEA level will be the efficacy measurement for endpoints and will be performed within every 3 months before the first treatment and repeated every 3 months in the first and second year and every 6 months thereafter. CT or MRI can be performed annually in the first 2 years or on suspected disease recurrence. The acceptable window for scheduling the imaging studies is ±1 week. Thereafter, CT or MRI will be performed only on suspected disease recurrence. DFS will be measured from start from the date of randomization to the date of disease recurrence</offsets></p></list-item><list-item><p><offsets xml_i="37782" xml_f="37813" txt_i="22053" txt_f="22084">Five-year overall survival (OS)</offsets></p><p><offsets xml_i="37820" xml_f="37906" txt_i="22085" txt_f="22171">OS will be measured from the start from the date of randomization to the date of death</offsets></p></list-item><list-item><p><offsets xml_i="37936" xml_f="37950" txt_i="22172" txt_f="22186">Safety profile</offsets></p><p><offsets xml_i="37957" xml_f="38298" txt_i="22187" txt_f="22528">Hematological and biochemical tests should be closely monitored during the treatment period because bone marrow depression, liver dysfunction, dehydration, anorexia, nausea, vomiting, and other AEs that have been reported in clinical treatment. The evaluation results would be included in the date or symptoms mentioned in the package insert</offsets></p></list-item></list><offsets xml_i="38321" xml_f="38322" txt_i="22529" txt_f="22530">
</offsets></p></sec><sec id="Sec34"><title><offsets xml_i="38355" xml_f="38388" txt_i="22532" txt_f="22565">Safety measurements and endpoints</offsets></title><p><offsets xml_i="38399" xml_f="38400" txt_i="22566" txt_f="22567">
</offsets><list list-type="bullet"><list-item><p><offsets xml_i="38439" xml_f="38466" txt_i="22567" txt_f="22594">Hematology and biochemistry</offsets></p><p><offsets xml_i="38473" xml_f="38614" txt_i="22595" txt_f="22736">Hematological and biochemical assessments will be performed within 7 days before enrollment and at each clinical visit, as reported in Table </offsets><xref rid="Tab3" ref-type="table"><offsets xml_i="38648" xml_f="38649" txt_i="22736" txt_f="22737">3</offsets></xref><offsets xml_i="38656" xml_f="38747" txt_i="22737" txt_f="22828">. The clinically relevant findings will be recorded and graded according to NCI-CTCAE v4.03</offsets><table-wrap id="Tab3"><label><offsets xml_i="38776" xml_f="38783" txt_i="22828" txt_f="22835">Table 3</offsets></label><caption><p><offsets xml_i="38803" xml_f="38863" txt_i="22835" txt_f="22895">Flowchart for pretreatment and post-treatment investigations</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th><offsets xml_i="38929" xml_f="38941" txt_i="22896" txt_f="22908">Study period</offsets></th><th><offsets xml_i="38950" xml_f="38959" txt_i="22908" txt_f="22917">Screening</offsets></th><th><offsets xml_i="38968" xml_f="38983" txt_i="22917" txt_f="22932">Study treatment</offsets></th><th><offsets xml_i="38992" xml_f="39012" txt_i="22932" txt_f="22952">Treatment completion</offsets></th><th colspan="2"><offsets xml_i="39033" xml_f="39047" txt_i="22952" txt_f="22966">Post treatment</offsets></th></tr><tr><th><offsets xml_i="39065" xml_f="39079" txt_i="22966" txt_f="22980">Day/month/year</offsets></th><th><offsets xml_i="39088" xml_f="39101" txt_i="22980" txt_f="22993">−28 to 0 days</offsets></th><th><offsets xml_i="39110" xml_f="39124" txt_i="22993" txt_f="23007">Clinical visit</offsets></th><th><offsets xml_i="39133" xml_f="39141" txt_i="23007" txt_f="23015">Any time</offsets></th><th><offsets xml_i="39150" xml_f="39158" txt_i="23015" txt_f="23023">2nd year</offsets></th><th><offsets xml_i="39167" xml_f="39180" txt_i="23023" txt_f="23036">3rd–5th years</offsets></th></tr></thead><tbody><tr><td><offsets xml_i="39213" xml_f="39229" txt_i="23036" txt_f="23052">Informed consent</offsets></td><td><offsets xml_i="39238" xml_f="39239" txt_i="23053" txt_f="23054">X</offsets></td><td></td><td></td><td></td><td></td></tr><tr><td><offsets xml_i="39293" xml_f="39308" txt_i="23059" txt_f="23074">Medical history</offsets></td><td><offsets xml_i="39317" xml_f="39318" txt_i="23075" txt_f="23076">X</offsets></td><td></td><td></td><td></td><td></td></tr><tr><td><offsets xml_i="39372" xml_f="39382" txt_i="23081" txt_f="23091">Demography</offsets></td><td><offsets xml_i="39391" xml_f="39392" txt_i="23092" txt_f="23093">X</offsets></td><td></td><td></td><td></td><td></td></tr><tr><td><offsets xml_i="39446" xml_f="39476" txt_i="23098" txt_f="23128">Pregnancy test, if appropriate</offsets></td><td><offsets xml_i="39485" xml_f="39486" txt_i="23129" txt_f="23130">X</offsets></td><td></td><td></td><td></td><td></td></tr><tr><td><offsets xml_i="39540" xml_f="39579" txt_i="23135" txt_f="23174">Physical examination, ECOG, vital signs</offsets></td><td><offsets xml_i="39588" xml_f="39589" txt_i="23175" txt_f="23176">X</offsets></td><td><offsets xml_i="39598" xml_f="39599" txt_i="23177" txt_f="23178">X</offsets><sup><offsets xml_i="39604" xml_f="39605" txt_i="23178" txt_f="23179">a</offsets></sup><offsets xml_i="39611" xml_f="39612" txt_i="23179" txt_f="23180">
</offsets></td><td><offsets xml_i="39621" xml_f="39622" txt_i="23181" txt_f="23182">X</offsets></td><td></td><td></td></tr><tr><td><offsets xml_i="39658" xml_f="39668" txt_i="23185" txt_f="23195">Hematology</offsets></td><td><offsets xml_i="39677" xml_f="39678" txt_i="23196" txt_f="23197">X</offsets></td><td><offsets xml_i="39687" xml_f="39688" txt_i="23198" txt_f="23199">X</offsets><sup><offsets xml_i="39693" xml_f="39694" txt_i="23199" txt_f="23200">a</offsets></sup><offsets xml_i="39700" xml_f="39701" txt_i="23200" txt_f="23201">
</offsets></td><td><offsets xml_i="39710" xml_f="39711" txt_i="23202" txt_f="23203">X</offsets></td><td></td><td></td></tr><tr><td><offsets xml_i="39747" xml_f="39759" txt_i="23206" txt_f="23218">Biochemistry</offsets></td><td><offsets xml_i="39768" xml_f="39769" txt_i="23219" txt_f="23220">X</offsets></td><td><offsets xml_i="39778" xml_f="39779" txt_i="23221" txt_f="23222">X</offsets><sup><offsets xml_i="39784" xml_f="39785" txt_i="23222" txt_f="23223">a</offsets></sup><offsets xml_i="39791" xml_f="39792" txt_i="23223" txt_f="23224">
</offsets></td><td><offsets xml_i="39801" xml_f="39802" txt_i="23225" txt_f="23226">X</offsets></td><td></td><td></td></tr><tr><td><offsets xml_i="39838" xml_f="39847" txt_i="23229" txt_f="23238">CT or MRI</offsets><sup><offsets xml_i="39852" xml_f="39853" txt_i="23238" txt_f="23239">b</offsets></sup><offsets xml_i="39859" xml_f="39860" txt_i="23239" txt_f="23240">
</offsets></td><td><offsets xml_i="39869" xml_f="39870" txt_i="23241" txt_f="23242">X</offsets></td><td></td><td><offsets xml_i="39888" xml_f="39889" txt_i="23244" txt_f="23245">X</offsets></td><td><offsets xml_i="39898" xml_f="39899" txt_i="23246" txt_f="23247">X</offsets></td><td></td></tr><tr><td><offsets xml_i="39926" xml_f="39940" txt_i="23249" txt_f="23263">Abdominal echo</offsets><sup><offsets xml_i="39945" xml_f="39946" txt_i="23263" txt_f="23264">c</offsets></sup><offsets xml_i="39952" xml_f="39953" txt_i="23264" txt_f="23265">
</offsets></td><td></td><td><offsets xml_i="39971" xml_f="39972" txt_i="23267" txt_f="23268">X</offsets><sup><offsets xml_i="39977" xml_f="39978" txt_i="23268" txt_f="23269">c</offsets></sup><offsets xml_i="39984" xml_f="39985" txt_i="23269" txt_f="23270">
</offsets></td><td></td><td><offsets xml_i="40003" xml_f="40017" txt_i="23272" txt_f="23286">Every 6 months</offsets></td><td><offsets xml_i="40026" xml_f="40040" txt_i="23287" txt_f="23301">Every 6 months</offsets></td></tr><tr><td><offsets xml_i="40058" xml_f="40088" txt_i="23302" txt_f="23332">Carcinoembryonic antigen (CEA)</offsets></td><td><offsets xml_i="40097" xml_f="40098" txt_i="23333" txt_f="23334">X</offsets></td><td><offsets xml_i="40107" xml_f="40108" txt_i="23335" txt_f="23336">X</offsets><sup><offsets xml_i="40113" xml_f="40114" txt_i="23336" txt_f="23337">a</offsets></sup><offsets xml_i="40120" xml_f="40121" txt_i="23337" txt_f="23338">
</offsets></td><td><offsets xml_i="40130" xml_f="40131" txt_i="23339" txt_f="23340">X</offsets></td><td><offsets xml_i="40140" xml_f="40154" txt_i="23341" txt_f="23355">Every 3 months</offsets></td><td><offsets xml_i="40163" xml_f="40177" txt_i="23356" txt_f="23370">Every 6 months</offsets></td></tr><tr><td><offsets xml_i="40195" xml_f="40210" txt_i="23371" txt_f="23386">Study treatment</offsets><sup><offsets xml_i="40215" xml_f="40216" txt_i="23386" txt_f="23387">d</offsets></sup><offsets xml_i="40222" xml_f="40223" txt_i="23387" txt_f="23388">
</offsets></td><td></td><td><offsets xml_i="40241" xml_f="40242" txt_i="23390" txt_f="23391">X</offsets></td><td></td><td></td><td></td></tr><tr><td><offsets xml_i="40287" xml_f="40301" txt_i="23395" txt_f="23409">Adverse events</offsets></td><td></td><td><offsets xml_i="40319" xml_f="40320" txt_i="23411" txt_f="23412">X</offsets></td><td><offsets xml_i="40329" xml_f="40330" txt_i="23413" txt_f="23414">X</offsets><sup><offsets xml_i="40335" xml_f="40336" txt_i="23414" txt_f="23415">e</offsets></sup><offsets xml_i="40342" xml_f="40343" txt_i="23415" txt_f="23416">
</offsets></td><td></td><td></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="40407" xml_f="40408" txt_i="23419" txt_f="23420">
</offsets><sup><offsets xml_i="40413" xml_f="40414" txt_i="23420" txt_f="23421">a</offsets></sup><offsets xml_i="40420" xml_f="40640" txt_i="23421" txt_f="23641">It will be repeated once every 3 months, including the assessment of physical status, Eastern Cooperative Oncology Group (ECOG) status, vital signs, hematological and biochemical data, and CEA, during the study treatment</offsets></p><p><offsets xml_i="40647" xml_f="40648" txt_i="23642" txt_f="23643">
</offsets><sup><offsets xml_i="40653" xml_f="40654" txt_i="23643" txt_f="23644">b</offsets></sup><offsets xml_i="40660" xml_f="40889" txt_i="23644" txt_f="23873">Computed tomography (CT) or magnetic resonance imaging (MRI) will be repeated every 12 months for the first 2 years or on suspecting disease recurrence. Thereafter, CT or MRI will be performed only on suspected disease recurrence</offsets></p><p><offsets xml_i="40896" xml_f="40897" txt_i="23874" txt_f="23875">
</offsets><sup><offsets xml_i="40902" xml_f="40903" txt_i="23875" txt_f="23876">c</offsets></sup><offsets xml_i="40909" xml_f="41226" txt_i="23876" txt_f="24193">Abdominal echo will be repeated every 6 months. However, actual implementation will be based on clinical practice. The schedule of CT or MRI and abdominal echo are crossed over; the examinations are typically performed at an interval of 6 months. CT or MRI is the main examination used when the schedule is duplicated</offsets></p><p><offsets xml_i="41233" xml_f="41234" txt_i="24194" txt_f="24195">
</offsets><sup><offsets xml_i="41239" xml_f="41240" txt_i="24195" txt_f="24196">d</offsets></sup><offsets xml_i="41246" xml_f="41318" txt_i="24196" txt_f="24268">Treatment in arm A will be started within 7 days after the randomization</offsets></p><p><offsets xml_i="41325" xml_f="41326" txt_i="24269" txt_f="24270">
</offsets><sup><offsets xml_i="41331" xml_f="41332" txt_i="24270" txt_f="24271">e</offsets></sup><offsets xml_i="41338" xml_f="41548" txt_i="24271" txt_f="24481">The patients will be followed for the occurrence of serious adverse events (SAEs) until 30 days after the last dose of study medication or introduction of an additional antitumor therapy, whichever occurs first</offsets></p></table-wrap-foot></table-wrap><offsets xml_i="41583" xml_f="41584" txt_i="24482" txt_f="24483">
</offsets></p></list-item><list-item><p><offsets xml_i="41614" xml_f="41630" txt_i="24484" txt_f="24500">Other toxicities</offsets></p><p><offsets xml_i="41637" xml_f="41779" txt_i="24501" txt_f="24643">Any toxicities other than those observed in hematological and biochemical assessments will be recorded and graded according to NCI-CTCAE v4.03</offsets></p></list-item></list><offsets xml_i="41802" xml_f="41803" txt_i="24644" txt_f="24645">
</offsets></p></sec></sec><sec id="Sec35"><title><offsets xml_i="41842" xml_f="41869" txt_i="24648" txt_f="24675">Assessment schedule (Table </offsets><xref rid="Tab3" ref-type="table"><offsets xml_i="41903" xml_f="41904" txt_i="24675" txt_f="24676">3</offsets></xref><offsets xml_i="41911" xml_f="41912" txt_i="24676" txt_f="24677">)</offsets></title><sec id="Sec36"><title><offsets xml_i="41943" xml_f="41982" txt_i="24678" txt_f="24717">Data management and statistical methods</offsets></title><sec id="Sec37"><title><offsets xml_i="42013" xml_f="42028" txt_i="24718" txt_f="24733">Data management</offsets></title><p><offsets xml_i="42039" xml_f="42434" txt_i="24734" txt_f="25129">CRFs will be provided for recording the data. Data will be recorded directly and legibly onto the CRFs by using a black-ink pen. If any data are unavailable, reason for omissions will be mentioned on the CRFs. Corrections will be made legibly and initiated and dated by an approved personnel; the reasons for marked changes will be provided. Correction fluid or covering labels will not be used.</offsets></p></sec><sec id="Sec38"><title><offsets xml_i="42467" xml_f="42516" txt_i="25131" txt_f="25180">Statistical methods and sample size determination</offsets></title><p><offsets xml_i="42527" xml_f="42746" txt_i="25181" txt_f="25400">This is an open-label, randomized, comparative, double-arm, multicenter, phase III study of tegafur-uracil following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection.</offsets><list list-type="order"><list-item><p><offsets xml_i="42784" xml_f="42806" txt_i="25400" txt_f="25422">Statistical evaluation</offsets></p></list-item><list-item><p><offsets xml_i="42836" xml_f="42864" txt_i="25423" txt_f="25451">Statistical analysis methods</offsets></p><p><offsets xml_i="42871" xml_f="43100" txt_i="25452" txt_f="25681">A comprehensive statistical analysis plan will be prepared before database lock. The patients will be categorized into the Full Analysis Set (FAS), per protocol (PP), and safety populations according to the following definitions:</offsets><list list-type="bullet"><list-item><label></label><p><offsets xml_i="43154" xml_f="43178" txt_i="25681" txt_f="25705">Full Analysis Set (FAS):</offsets></p><p><offsets xml_i="43185" xml_f="43472" txt_i="25706" txt_f="25993">The FAS is defined as containing all registered and randomized patients who received at least one dose of the study treatment without major protocol violations, such as noncompliance with the eligibility criteria, or other major violations (defined before database lock) during the study</offsets></p></list-item><list-item><label></label><p><offsets xml_i="43517" xml_f="43539" txt_i="25994" txt_f="26016">Intent-to-treat (ITT):</offsets></p><p><offsets xml_i="43546" xml_f="43667" txt_i="26017" txt_f="26138">The ITT population is the subset of the FAS population, and as all randomized patients irrespective of treatment received</offsets></p></list-item><list-item><label></label><p><offsets xml_i="43712" xml_f="43730" txt_i="26139" txt_f="26157">Per protocol (PP):</offsets></p><p><offsets xml_i="43737" xml_f="44125" txt_i="26158" txt_f="26546">The PP population is the subset of the ITT population and subjects who complete 12 months of tegafur-uracil treatment/observation with at least one biomarker assessment post treatment. The subject with confirmed early disease recurrence/relapse would be included in the PP population. The patients with confirmed early disease recurrence and relapse will be included in the PP population.</offsets></p><p><offsets xml_i="44132" xml_f="44279" txt_i="26547" txt_f="26694">All the efficacy endpoints will be analyzed in the FAS and PP populations. The main assessment will be performed on the basis of the PP population.</offsets></p><p><offsets xml_i="44286" xml_f="44459" txt_i="26695" txt_f="26868">The safety population is defined as all patients who are exposed to at least one dose of the study treatment and who are available for obtaining follow-up safety information</offsets></p></list-item></list><offsets xml_i="44482" xml_f="44483" txt_i="26869" txt_f="26870">
</offsets></p></list-item><list-item><p><offsets xml_i="44513" xml_f="44533" txt_i="26871" txt_f="26891">Statistical analyses</offsets><list list-type="bullet"><list-item><label></label><p><offsets xml_i="44587" xml_f="44620" txt_i="26891" txt_f="26924">Demographic and baseline measures</offsets></p><p><offsets xml_i="44627" xml_f="45034" txt_i="26925" txt_f="27332">All demographic and baseline data will be summarized and listed in detail. For continuous variables, the descriptive statistics, including the patient number, mean, median, standard deviation, and range (minimum-maximum) will be presented; frequency tables will be displayed for categorical data. If demographic and baseline measures are significant, their inclusion in the analysis model will be considered</offsets></p></list-item><list-item><label></label><p><offsets xml_i="45079" xml_f="45117" txt_i="27333" txt_f="27371">Three-year disease-free survival (DFS)</offsets></p><p><offsets xml_i="45124" xml_f="45602" txt_i="27372" txt_f="27850">Three-year DFS will be defined as the percentage of patients alive without disease recurrence at 3 years measured from the randomization date. The 3-year DFS will be evaluated using the Kaplan-Meier method, and the analysis will be presented in descriptive statistics, presented by a point estimate and 95% confidence interval. The results will be summarized in the form of the sample size, mean, standard error, median, percentiles, and range by descriptive statistical methods</offsets></p></list-item><list-item><label></label><p><offsets xml_i="45647" xml_f="45678" txt_i="27851" txt_f="27882">Five-year overall survival (OS)</offsets></p><p><offsets xml_i="45685" xml_f="46139" txt_i="27883" txt_f="28337">Five-year OS will be defined as the percentage of patients alive at 5 years measured from the randomization date. The 5-year OS will be evaluated using the Kaplan-Meier method, and the analysis will be presented in descriptive statistics, presented by a point estimate and 95% confidence interval. The results will be summarized in the form of the sample size, mean, standard error, median, percentiles, and range by using descriptive statistical methods</offsets></p></list-item><list-item><label></label><p><offsets xml_i="46184" xml_f="46198" txt_i="28338" txt_f="28352">Safety profile</offsets></p><p><offsets xml_i="46205" xml_f="46528" txt_i="28353" txt_f="28676">AEs will be summarized using NCI-CTCAE v4.03 and the preferred term. The incidence and percentage of patients with at least one occurrence of a preferred term will be included according to the most severe NCI-CTCAE v4.03 grade. Laboratorial toxicity will be presented according to the highest NCI-CTCAE v4.03 grade by cycle</offsets></p></list-item></list><offsets xml_i="46551" xml_f="46552" txt_i="28677" txt_f="28678">
</offsets></p></list-item></list><offsets xml_i="46575" xml_f="46576" txt_i="28679" txt_f="28680">
</offsets></p></sec></sec><sec id="Sec39"><title><offsets xml_i="46615" xml_f="46629" txt_i="28683" txt_f="28697">Adverse events</offsets></title><p><offsets xml_i="46640" xml_f="46852" txt_i="28698" txt_f="28910">Timely, accurate, and complete reporting and analysis of safety information from clinical studies are crucial for the treatment of patients and for investigators and are mandated by regulatory agencies worldwide.</offsets></p></sec><sec id="Sec40"><title><offsets xml_i="46885" xml_f="46896" txt_i="28912" txt_f="28923">Definitions</offsets></title><p><offsets xml_i="46907" xml_f="46908" txt_i="28924" txt_f="28925">
</offsets><list list-type="order"><list-item><p><offsets xml_i="46946" xml_f="46960" txt_i="28925" txt_f="28939">Adverse events</offsets></p><p><offsets xml_i="46967" xml_f="47367" txt_i="28940" txt_f="29340">An AE is defined as any untoward medical occurrence in a clinical study patient administered a pharmaceutical product, and it does not necessarily have a causal relationship with the treatment. Therefore, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of an IP, whether related to the product or not.</offsets></p><p><offsets xml_i="47374" xml_f="47436" txt_i="29341" txt_f="29403">Definition per International Conference on Harmonization (ICH)</offsets></p><p><offsets xml_i="47443" xml_f="47640" txt_i="29404" txt_f="29601">An AE is any occurrence that is new in onset or aggravated in severity or frequency from the baseline condition or abnormal results of diagnostic procedures, including laboratory test abnormalities</offsets></p></list-item><list-item><p><offsets xml_i="47670" xml_f="47693" txt_i="29602" txt_f="29625">Serious adverse events:</offsets></p><p><offsets xml_i="47700" xml_f="47840" txt_i="29626" txt_f="29766">A serious adverse event (SAE), as defined by ICH, is any untoward medical occurrence that at any dose meets any of the following conditions:</offsets><list list-type="bullet"><list-item><label></label><p><offsets xml_i="47894" xml_f="47910" txt_i="29766" txt_f="29782">Results in death</offsets></p></list-item><list-item><label></label><p><offsets xml_i="47955" xml_f="48226" txt_i="29783" txt_f="30054">Is life-threatening (note: the term life-threatening in the definition of severe refers to an event, in which the patients are at a risk of death at the time of the event; it does not refer to an event, which hypothetically might have caused death if it were more severe)</offsets></p></list-item><list-item><label></label><p><offsets xml_i="48271" xml_f="48349" txt_i="30055" txt_f="30133">Requires inpatient hospitalization or prolongation of existing hospitalization</offsets></p></list-item><list-item><label></label><p><offsets xml_i="48394" xml_f="48450" txt_i="30134" txt_f="30190">Results in persistent or marked disability or incapacity</offsets></p></list-item><list-item><label></label><p><offsets xml_i="48495" xml_f="48534" txt_i="30191" txt_f="30230">Is a congenital anomaly or birth defect</offsets></p></list-item><list-item><label></label><p><offsets xml_i="48579" xml_f="48650" txt_i="30231" txt_f="30302">Requires medical intervention to prevent permanent impairment or damage</offsets></p></list-item><list-item><label></label><p><offsets xml_i="48695" xml_f="49346" txt_i="30303" txt_f="30954">Medical and scientific judgment will be exercised in deciding whether expedited reporting is appropriate in other situations, such as crucial medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize patient health or require intervention to prevent one of the other outcomes listed in the aforementioned definition. These events will also typically be considered severe. Examples of such events are intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, or development of drug dependency or abuse</offsets></p></list-item></list><offsets xml_i="49369" xml_f="49370" txt_i="30955" txt_f="30956">
</offsets></p></list-item><list-item><p><offsets xml_i="49400" xml_f="49437" txt_i="30957" txt_f="30994">Unlisted or unexpected adverse events</offsets></p><p><offsets xml_i="49444" xml_f="49683" txt_i="30995" txt_f="31234">The characteristic or severity of an unlisted or unexpected AE is not consistent with the applicable product information. For an IP, the expectedness of an AE will be determined by whether or not it is listed in the investigator’s brochure</offsets></p></list-item><list-item><p><offsets xml_i="49713" xml_f="49744" txt_i="31235" txt_f="31266">Reversibility of adverse events</offsets></p><p><offsets xml_i="49751" xml_f="49960" txt_i="31267" txt_f="31476">AE disappearance is defined as an absence of AEs or recovery of AE severity to baseline values. AE alleviation is defined as the recovery of severity to grade 1 and is applicable for grade 2 or higher AEs only</offsets></p></list-item></list><offsets xml_i="49983" xml_f="49984" txt_i="31477" txt_f="31478">
</offsets></p></sec><sec id="Sec41"><title><offsets xml_i="50017" xml_f="50026" txt_i="31480" txt_f="31489">Reporting</offsets></title><p><offsets xml_i="50037" xml_f="50038" txt_i="31490" txt_f="31491">
</offsets><list list-type="order"><list-item><p><offsets xml_i="50076" xml_f="50099" txt_i="31491" txt_f="31514">Adverse event reporting</offsets></p><p><offsets xml_i="50106" xml_f="50260" txt_i="31515" txt_f="31669">All AEs will be reported from the time that a signed and dated Informed Consent Form is obtained until the completion of the last study-related procedure.</offsets></p><p><offsets xml_i="50267" xml_f="50734" txt_i="31670" txt_f="32137">All AEs, regardless of their seriousness, severity, or presumed relationship to the study therapy, will be recorded using medical terminology in the source document and CRF. Whenever possible, diagnoses will be performed if signs and symptoms are caused by a common etiology. Investigators will record in the CRF their opinions concerning the relationship of the AE to the study therapy. All measures required for AE management will be recorded in the source document</offsets></p></list-item><list-item><p><offsets xml_i="50764" xml_f="50786" txt_i="32138" txt_f="32160">Severity and causality</offsets></p><p><offsets xml_i="50793" xml_f="50887" txt_i="32161" txt_f="32255">AE severity and relationship to the study medication will be evaluated and recorded in the CRF</offsets><list list-type="bullet"><list-item><label></label><p><offsets xml_i="50941" xml_f="50968" txt_i="32255" txt_f="32282">Severity categories (Table </offsets><xref rid="Tab4" ref-type="table"><offsets xml_i="51002" xml_f="51003" txt_i="32282" txt_f="32283">4</offsets></xref><offsets xml_i="51010" xml_f="51011" txt_i="32283" txt_f="32284">)</offsets><table-wrap id="Tab4"><label><offsets xml_i="51040" xml_f="51047" txt_i="32284" txt_f="32291">Table 4</offsets></label><caption><p><offsets xml_i="51067" xml_f="51110" txt_i="32291" txt_f="32334">Severity categories of adverse events (AEs)</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th><offsets xml_i="51176" xml_f="51184" txt_i="32335" txt_f="32343">Severity</offsets></th><th><offsets xml_i="51193" xml_f="51204" txt_i="32343" txt_f="32354">Description</offsets></th></tr></thead><tbody><tr><td rowspan="2"><offsets xml_i="51249" xml_f="51253" txt_i="32354" txt_f="32358">Mild</offsets></td><td><offsets xml_i="51262" xml_f="51285" txt_i="32359" txt_f="32382">NCI-CTCAE v4.03 grade 1</offsets></td></tr><tr><td><offsets xml_i="51303" xml_f="51388" txt_i="32383" txt_f="32468">The AE does not limit daily activities; the patients may experience slight discomfort</offsets></td></tr><tr><td rowspan="2"><offsets xml_i="51418" xml_f="51426" txt_i="32469" txt_f="32477">Moderate</offsets></td><td><offsets xml_i="51435" xml_f="51458" txt_i="32478" txt_f="32501">NCI-CTCAE v4.03 grade 2</offsets></td></tr><tr><td><offsets xml_i="51476" xml_f="51582" txt_i="32502" txt_f="32608">The AE results in some limitation of daily activities; the patients may experience considerable discomfort</offsets></td></tr><tr><td rowspan="2"><offsets xml_i="51612" xml_f="51618" txt_i="32609" txt_f="32615">Severe</offsets></td><td><offsets xml_i="51627" xml_f="51650" txt_i="32616" txt_f="32639">NCI-CTCAE v4.03 grade 3</offsets></td></tr><tr><td><offsets xml_i="51668" xml_f="51778" txt_i="32640" txt_f="32750">The AE results in an inability to perform daily activities; the patients may experience intolerable discomfort</offsets></td></tr><tr><td rowspan="3"><offsets xml_i="51808" xml_f="51834" txt_i="32751" txt_f="32777">Life-threatening/disabling</offsets></td><td><offsets xml_i="51843" xml_f="51866" txt_i="32778" txt_f="32801">NCI-CTCAE v4.03 grade 4</offsets></td></tr><tr><td><offsets xml_i="51884" xml_f="51923" txt_i="32802" txt_f="32841">The AE results in a disabling situation</offsets></td></tr><tr><td><offsets xml_i="51941" xml_f="51987" txt_i="32842" txt_f="32888">The AE results in a life-threatening situation</offsets></td></tr><tr><td><offsets xml_i="52005" xml_f="52010" txt_i="32889" txt_f="32894">Death</offsets></td><td><offsets xml_i="52019" xml_f="52042" txt_i="32895" txt_f="32918">NCI-CTCAE v4.03 grade 5</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="52088" xml_f="52343" txt_i="32919" txt_f="33174">*The term life-threatening in the definition of severe refers to an event, in which the patients are at a risk of death at the time of the event; it does not refer to an event which, hypothetically, might have caused death if it were more severe (ICH-E2A)</offsets></p></table-wrap-foot></table-wrap><offsets xml_i="52378" xml_f="52379" txt_i="33175" txt_f="33176">
</offsets></p></list-item><list-item><label></label><p><offsets xml_i="52424" xml_f="53107" txt_i="33177" txt_f="33860">Causality to study medication The causal relationship with the study medication will be judged considering a patient’s systemic conditions, complications, concomitant medications, combination therapies, and temporal relationship. A reasonable possibility of the relationship between an AE and the study medication will be categorized into two categories: yes (presence of a reasonable causal relationship) or no (absence of a reasonable causal relationship; refer to the Council for International Organizations of Medical Sciences for definition of causality VI. If the investigator judges the relationship to be a “yes,” the event will be considered an adverse drug reaction (Table </offsets><xref rid="Tab5" ref-type="table"><offsets xml_i="53141" xml_f="53142" txt_i="33860" txt_f="33861">5</offsets></xref><offsets xml_i="53149" xml_f="53151" txt_i="33861" txt_f="33863">).</offsets><table-wrap id="Tab5"><label><offsets xml_i="53180" xml_f="53187" txt_i="33863" txt_f="33870">Table 5</offsets></label><caption><p><offsets xml_i="53207" xml_f="53234" txt_i="33870" txt_f="33897">Adverse drug reaction (ADR)</offsets></p></caption><table frame="hsides" rules="groups"><tbody><tr><td><offsets xml_i="53300" xml_f="53309" txt_i="33898" txt_f="33907">Unrelated</offsets></td><td><offsets xml_i="53318" xml_f="53371" txt_i="33908" txt_f="33961">An adverse event (AE) that is not related to drug use</offsets></td></tr><tr><td><offsets xml_i="53389" xml_f="53397" txt_i="33962" txt_f="33970">Unlikely</offsets></td><td><offsets xml_i="53406" xml_f="53579" txt_i="33971" txt_f="34144">An AE for which an alternative explanation is more likely (e.g., concomitant drugs and diseases), or the relationship in time suggests that a causal relationship is unlikely</offsets></td></tr><tr><td><offsets xml_i="53597" xml_f="53605" txt_i="34145" txt_f="34153">Possible</offsets></td><td><offsets xml_i="53614" xml_f="53830" txt_i="34154" txt_f="34370">An AE that might be caused by drug use. An alternative explanation (e.g., concomitant drugs and diseases) is inconclusive. The relationship in time is reasonable; therefore, the causal relationship cannot be excluded</offsets></td></tr><tr><td><offsets xml_i="53848" xml_f="53866" txt_i="34371" txt_f="34389">Probable or likely</offsets></td><td><offsets xml_i="53875" xml_f="54066" txt_i="34390" txt_f="34581">An AE that might be due to drug use. The relationship in time is suggestive (e.g., confirmed by a dechallenge). An alternative explanation is less likely (e.g., concomitant drugs or diseases)</offsets></td></tr><tr><td><offsets xml_i="54084" xml_f="54091" txt_i="34582" txt_f="34589">Certain</offsets></td><td><offsets xml_i="54100" xml_f="54339" txt_i="34590" txt_f="34829">An AE that is listed as a possible ADR and cannot be reasonably explained by an alternative explanation (e.g., concomitant drugs and diseases). The relationship in time is highly suggestive; it is confirmed by a dechallenge and rechallenge</offsets></td></tr></tbody></table></table-wrap><offsets xml_i="54378" xml_f="54379" txt_i="34830" txt_f="34831">
</offsets></p></list-item></list><offsets xml_i="54402" xml_f="54403" txt_i="34832" txt_f="34833">
</offsets></p></list-item><list-item><p><offsets xml_i="54433" xml_f="54464" txt_i="34834" txt_f="34865">Serious adverse event reporting</offsets></p><p><offsets xml_i="54471" xml_f="54621" txt_i="34866" txt_f="35016">All SAEs occurring during clinical studies will be reported to the IRBs by the investigational staff within the timeframe required by individual IRBs.</offsets></p><p><offsets xml_i="54628" xml_f="55018" txt_i="35017" txt_f="35407">The cause of death of a patient in a clinical study, whether or not the event is expected or associated with the IP, is considered an SAE. Any event requiring hospitalization (or prolongation of hospitalization and exceeds a 24-h emergency visit) that occurs during a patient’s participation in a clinical study will be reported as an SAE, except hospitalizations for the following reasons:</offsets><list list-type="bullet"><list-item><label></label><p><offsets xml_i="55072" xml_f="55110" txt_i="35407" txt_f="35445">Social reasons in the absence of an AE</offsets></p></list-item><list-item><label></label><p><offsets xml_i="55155" xml_f="55752" txt_i="35446" txt_f="36043">Surgery or procedure planned before the study entry will be documented in the CRF Note: medical and scientific judgment will be exercised in deciding whether expedited reporting is appropriate in situations other than those listed above. For example, crucial medical events may not be immediately life-threatening or result in death or hospitalization but may jeopardize patient health or require intervention to prevent one of the aforementioned outcomes. Any AE is considered severe if it is associated with clinical signs or symptoms judged by the investigator to exert a marked clinical effect</offsets></p></list-item></list><offsets xml_i="55775" xml_f="55776" txt_i="36044" txt_f="36045">
</offsets></p></list-item></list><offsets xml_i="55799" xml_f="55800" txt_i="36046" txt_f="36047">
</offsets></p></sec><sec id="Sec42"><title><offsets xml_i="55833" xml_f="55842" txt_i="36049" txt_f="36058">Follow-up</offsets></title><p><offsets xml_i="55853" xml_f="55854" txt_i="36059" txt_f="36060">
</offsets><list list-type="order"><list-item><p><offsets xml_i="55892" xml_f="56101" txt_i="36060" txt_f="36269">For safe follow-up, each patient will be followed for the occurrence of SAEs until 30 days after the last dose of the study medication or introduction of an additional antitumor therapy, whichever occurs first</offsets></p></list-item><list-item><p><offsets xml_i="56131" xml_f="56311" txt_i="36270" txt_f="36450">All SAEs that have not been resolved by the end of the study or upon discontinuation of the patient’s participation in the study will be followed until any of the following occurs:</offsets><list list-type="bullet"><list-item><label></label><p><offsets xml_i="56365" xml_f="56386" txt_i="36450" txt_f="36471">The event is resolved</offsets></p></list-item><list-item><label></label><p><offsets xml_i="56431" xml_f="56454" txt_i="36472" txt_f="36495">The event is stabilized</offsets></p></list-item><list-item><label></label><p><offsets xml_i="56499" xml_f="56571" txt_i="36496" txt_f="36568">The event severity returns to baseline, if a baseline value is available</offsets></p></list-item><list-item><label></label><p><offsets xml_i="56616" xml_f="56733" txt_i="36569" txt_f="36686">The event can be attributed to agents other than the study medication or to factors unrelated to the study procedures</offsets></p></list-item><list-item><label></label><p><offsets xml_i="56778" xml_f="56985" txt_i="36687" txt_f="36894">When obtaining additional information is unlikely (the patients or health care practitioners refuse to provide additional information or the patients are lost to follow-up despite diligent follow-up efforts)</offsets></p></list-item></list><offsets xml_i="57008" xml_f="57009" txt_i="36895" txt_f="36896">
</offsets></p></list-item></list><offsets xml_i="57032" xml_f="57033" txt_i="36897" txt_f="36898">
</offsets></p></sec><sec id="Sec43"><title><offsets xml_i="57066" xml_f="57082" txt_i="36900" txt_f="36916">Pregnancy report</offsets></title><p><offsets xml_i="57093" xml_f="57586" txt_i="36917" txt_f="37410">Patient pregnancy will be reported by the investigational staff within 24 h of their knowledge. The study medication may affect pregnancies in partners of male patients included in the study; therefore, it will be reported by the investigational staff within 24 h of their knowledge. Any patient who becomes pregnant during the study will be promptly withdrawn from the study. Follow-up information regarding outcomes of the pregnancy and any postnatal sequelae in the infant will be reported.</offsets></p></sec><sec id="Sec44"><title><offsets xml_i="57619" xml_f="57641" txt_i="37412" txt_f="37434">Good Clinical Practice</offsets></title><p><offsets xml_i="57652" xml_f="57960" txt_i="37435" txt_f="37743">The trial will be conducted in accordance with the World Medical Association’s Declaration of Helsinki, as amended in 1996, and Good Clinical Practice (GCP) principles, as defined in the ICH of Technical Requirements for Registration of Pharmaceuticals for Human Use Harmonized Tripartite Guidelines for GCP.</offsets></p></sec><sec id="Sec45"><title><offsets xml_i="57993" xml_f="58028" txt_i="37745" txt_f="37780">Institutional Review Board approval</offsets></title><p><offsets xml_i="58039" xml_f="58223" txt_i="37781" txt_f="37965">The investigator will submit a copy of the protocol to the local IRB for consideration. The study will not start in each center until the IRB provides written approval of the protocol.</offsets></p></sec><sec id="Sec46"><title><offsets xml_i="58256" xml_f="58279" txt_i="37967" txt_f="37990">Consent for publication</offsets></title><p><offsets xml_i="58290" xml_f="59442" txt_i="37991" txt_f="39143">The investigator will be responsible for providing written (Patient Information Sheets) and verbal information to the patient and obtaining written informed consent before conducting study-specific procedures for the patients enrolled in the trial. Informed consent will be presented in language comprehensible to the patients or their legally authorized representatives. The patients or their representatives will be provided with adequate time to read the completed informed consent and their questions will be addressed. Informed consent will be obtained in a noncoercive manner, and the patients will be informed that participation is voluntary and will not affect the care that they may otherwise receive. After obtaining the consent, the patients or their representatives will be asked to sign and date the Consent Form, and the investigator or other authorized individuals obtaining the consent will also sign and date the form. A copy of the completed Consent Form will be provided to the patients. The investigator will confirm in writing that informed consent has been obtained and that a copy of the Consent Form is provided to the patients.</offsets></p></sec><sec id="Sec47"><title><offsets xml_i="59475" xml_f="59502" txt_i="39145" txt_f="39172">Premature trial termination</offsets></title><p><offsets xml_i="59513" xml_f="59723" txt_i="39173" txt_f="39383">The regulatory authority, IRB, and the investigator have the right to terminate the trial at any time for reasonable medical and administrative reasons. Reasons for termination will be appropriately documented.</offsets></p></sec></sec><sec id="Sec48"><title><offsets xml_i="59762" xml_f="59772" txt_i="39386" txt_f="39396">Discussion</offsets></title><p><offsets xml_i="59783" xml_f="60066" txt_i="39397" txt_f="39674">CRC remains a leading form of cancer worldwide. In Taiwan, CRC is the most common cancer and the third leading cause of cancer-related deaths. The annual incidence of CRC in Taiwan has increased up to 43.5% in the past decade, with &gt;15,000 new cases and &gt;5000 deaths annually [</offsets><xref ref-type="bibr" rid="CR1"><offsets xml_i="60098" xml_f="60099" txt_i="39674" txt_f="39675">1</offsets></xref><offsets xml_i="60106" xml_f="60557" txt_i="39675" txt_f="40126">]. Randomized clinical trials have reported that the survival rate and quality of life in patients with stage III colon cancer who received chemotherapy were superior to those who were offered the most favorable supportive care alone. These observations support the use of different combination chemotherapy regimens. Moreover, novel therapeutic strategies are required to achieve more favorable clinical efficacy, with an acceptable toxicity profile.</offsets></p><p><offsets xml_i="60564" xml_f="60761" txt_i="40127" txt_f="40324">Oxaliplatin, a platinum derivative, shows synergism; it is a third-generation diaminocyclohexane platinum compound that inhibits replication and transcription through the formation of DNA adducts [</offsets><xref ref-type="bibr" rid="CR13"><offsets xml_i="60794" xml_f="60796" txt_i="40324" txt_f="40326">13</offsets></xref><offsets xml_i="60803" xml_f="61247" txt_i="40326" txt_f="40770">]. To achieve more desirable efficacy and safety in stage III colon cancer, adjuvant chemotherapy with 5-FU has become the standard treatment. To provide the most favorable care for all patients with stage III colon cancer, aggressive treatment guidelines are crucial. Oxaliplatin, 5-FU, and LV combination chemotherapy is accepted and was reported as an effective first-line treatment regimen for advanced or metastatic gastric cancer or CRC [</offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="61280" xml_f="61282" txt_i="40770" txt_f="40772">14</offsets></xref><offsets xml_i="61289" xml_f="61291" txt_i="40772" txt_f="40774">, </offsets><xref ref-type="bibr" rid="CR15"><offsets xml_i="61324" xml_f="61326" txt_i="40774" txt_f="40776">15</offsets></xref><offsets xml_i="61333" xml_f="61335" txt_i="40776" txt_f="40778">].</offsets></p><p><offsets xml_i="61342" xml_f="62096" txt_i="40779" txt_f="41533">After radical surgery and adjuvant chemotherapy, more intensive treatment must be considered for stage III colon cancer to achieve more desirable disease control and improved OS. However, maintenance tegafur-uracil versus observation following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection has not been highly altered in the last few decades. The efficacy and safety of chemotherapeutic agents are fundamental aspects of treating patients with stage III colon cancer. In this study, we set 3-year DFS and 5-year OS as the primary endpoints for evaluation to determine the effects of maintenance tegafur-uracil following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer.</offsets></p><p><offsets xml_i="62103" xml_f="62694" txt_i="41534" txt_f="42125">In summary, adjuvant chemotherapy with oxaliplatin and tegafur-uracil is safe and has remarkable treatment efficacy, with the advantage of yielding a favorable response rate and a tolerable toxicity profile. We recognize that although observational studies provide some valuable information, they are not adequately capable of providing credible evidence. This observation, in addition to the limitations derived from the retrospective data collected from medical charts and lack of a control group, entails the urgent need to perform prospectively randomized studies to confirm the results.</offsets></p><p><offsets xml_i="62701" xml_f="62877" txt_i="42126" txt_f="42302">Additional trials are required to confirm the benefits of tegafur-uracil administration following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer.</offsets></p><sec id="Sec49"><title><offsets xml_i="62904" xml_f="62916" txt_i="42303" txt_f="42315">Trial status</offsets></title><p><offsets xml_i="62927" xml_f="63053" txt_i="42316" txt_f="42442">The trial started in July 2016 and is expected to enroll 546 patients in the study and control groups by the end of July 2018.</offsets></p></sec></sec></body><back><app-group><app id="App1"><sec id="Sec50"><title>Additional file</title><p>
<media position="anchor" xlink:href="13063_2017_1904_MOESM1_ESM.pdf" id="MOESM1"><label>Additional file 1:</label><caption><p>Submission of a populated SPIRIT Checklist [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. This is an open-label, randomized, multicenter study of tegafur-uracil following adjuvant oxaliplatin-based regimen in patients with stage III colon cancer patients after radical resection. (PDF 53 kb)</p></caption></media>
</p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>5-FU</term><def><p>Fluorouracil</p></def></def-item><def-item><term>ADR</term><def><p>Adverse drug reaction</p></def></def-item><def-item><term>AE</term><def><p>Adverse event</p></def></def-item><def-item><term>AJCC</term><def><p>American Joint Committee on Cancer</p></def></def-item><def-item><term>ALT</term><def><p>Alanine aminotransferase</p></def></def-item><def-item><term>ANC</term><def><p>Absolute neutrophil count</p></def></def-item><def-item><term>AST</term><def><p>Aspartate aminotransferase</p></def></def-item><def-item><term>BUN</term><def><p>Blood urea nitrogen</p></def></def-item><def-item><term>CBC</term><def><p>Complete blood count</p></def></def-item><def-item><term>CEA</term><def><p>Carcinoembryonic antigen</p></def></def-item><def-item><term>CIOMS</term><def><p>Council for International Organizations of Medical Sciences</p></def></def-item><def-item><term>CRC</term><def><p>Colorectal cancer</p></def></def-item><def-item><term>CRF</term><def><p>Case Report Form</p></def></def-item><def-item><term>CT</term><def><p>Computed tomography</p></def></def-item><def-item><term>CTCAE</term><def><p>Common Terminology Criteria for Adverse Events</p></def></def-item><def-item><term>D/C</term><def><p>Differentiation count</p></def></def-item><def-item><term>DFS</term><def><p>Disease-free survival</p></def></def-item><def-item><term>DNA</term><def><p>Deoxyribonucleic acid</p></def></def-item><def-item><term>ECOG</term><def><p>Eastern Cooperative Oncology Group</p></def></def-item><def-item><term>FAS</term><def><p>Full Analysis Set</p></def></def-item><def-item><term>FdUMP</term><def><p>5-Fluoro-2’-deoxyuridine monophosphate</p></def></def-item><def-item><term>FOLFOX</term><def><p>Folinic acid/fluorouracil/oxaliplatin</p></def></def-item><def-item><term>FUTP</term><def><p>5-Fluorouridine triphosphate</p></def></def-item><def-item><term>GCP</term><def><p>Good Clinical Practice</p></def></def-item><def-item><term>ICH</term><def><p>International Conference on Harmonization</p></def></def-item><def-item><term>IP</term><def><p>Investigational product</p></def></def-item><def-item><term>IRB</term><def><p>Institutional Review Board</p></def></def-item><def-item><term>LV</term><def><p>Leucovorin</p></def></def-item><def-item><term>MOSAIC</term><def><p>The Multicenter International Study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon cancer</p></def></def-item><def-item><term>MRI</term><def><p>Magnetic resonance imaging</p></def></def-item><def-item><term>OS</term><def><p>Overall survival</p></def></def-item><def-item><term>PP</term><def><p>Per protocol</p></def></def-item><def-item><term>RNA</term><def><p>Ribonucleic acid</p></def></def-item><def-item><term>SAE</term><def><p>Serious adverse event</p></def></def-item><def-item><term>ULN</term><def><p>Upper limit of normal</p></def></def-item><def-item><term>UTP</term><def><p>Triphosphate</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>This study is supported by grants from TTY Biopharm Company Limited, grants from the Excellence for Cancer Research Center through funding by the Ministry of Science and Technology (MOST105-2325-B-037-001) and the Ministry of Health and Welfare (MOHW106-TDU-B-212-144007); Health and Welfare Surcharge of Tobacco Products, Taiwan, Republic of China; and Kaohsiung Medical University Hospital (KMUH104-4 M27, KMUH105-5M19, KMUH105-5R26, KMUH98-8G06, KMHU100-0 M14, KMUHS10522, KMUHS10505, KMUHS10418, and KMUHGCRC2016002). The study was supported by the Kaohsiung Medical University “Aim for the top University Grant” (KMU-TP105C01, KMU-TP105C11, KMU-TP106005, KMU-TP105A14, KMU-DK106005, and SH000113 [Give2Asia]) and the Grant from Biosignature in Colorectal Cancers, Academia Sinica, Taiwan.</p><sec id="FPar1"><title>Funding</title><p>This protocol is a type of investigator initiated research (IIR), and no external funding was included.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p>Comparison of adjuvant FOLFOX4 chemotherapy versus orally administered UFT/LV following adjuvant FOLFOX4 chemotherapy in stage III colon cancer patients after radical resection. Oncology Letters. 2016 (accepted).</p></sec><sec id="FPar3"><title>Authors’ contributions</title><p>All of the authors participated in the trial design. YS wrote the study protocol and helped to draft the manuscript. HL contributed to the statistical methods and the analysis. CW carried out the molecular genetic studies and immunoassays. PL conceived of the study and participated in its design. YC participated in the design and coordination of the study. HC participated in the sequence alignment. JY critically revised the manuscript. All of the authors read and approved the final version of the manuscript.</p></sec><sec id="FPar4"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar5"><title>Consent for publication</title><p>On behalf of all co-authors, the corresponding author has obtained the consent for publication.</p></sec><sec id="FPar6"><title>Ethics approval and consent to participate</title><p>In compliance with the Helsinki Declaration, this study was approved by Institutional Review Board of Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan (IRB number: IRB-F(I)-20160016). We will obtain informed consent from each participant.</p><p>The investigator will be responsible for providing written (Patient Information Sheets) and verbal information to the patient and obtaining written informed consent before conducting study-specific procedures for the patients enrolled in the trial. Informed consent will be presented in language comprehensible to the patients or their legally authorized representatives. The patients or their representatives will be provided with adequate time to read the completed informed consent and their questions will be addressed. Informed consent will be obtained in a noncoercive manner, and the patients will be informed that participation is voluntary and will not affect the care that they may otherwise receive. After obtaining the consent, the patients or their representatives will be asked to sign and date the Consent Form, and the investigator or other authorized individuals obtaining the consent will also sign and date the form. A copy of the completed Consent Form will be provided to the patients. The investigator will confirm in writing that informed consent has been obtained and that a copy of the consent is provided to the patients.</p></sec><sec id="FPar7"><title>Publisher’s Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Taiwan Cancer Registry Database. <ext-link ext-link-type="uri" xlink:href="http://tcr.cph.ntu.edu.tw/main.php?Page=N1">http://tcr.cph.ntu.edu.tw/main.php?Page=N1</ext-link>. 2016.</mixed-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>CJ</given-names></name><name><surname>Lo</surname><given-names>WC</given-names></name><name><surname>Yang</surname><given-names>YW</given-names></name><name><surname>You</surname><given-names>SL</given-names></name><name><surname>Chen</surname><given-names>CJ</given-names></name><name><surname>Lai</surname><given-names>MS</given-names></name></person-group><article-title>Incidence and survival of adult cancer patients in Taiwan, 2002–2012</article-title><source>J Formos Med Assoc</source><year>2016</year><volume>115</volume><issue>12</issue><fpage>1076</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.jfma.2015.10.011</pub-id><pub-id pub-id-type="pmid">26786251</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sargent</surname><given-names>DJ</given-names></name><name><surname>Patiyil</surname><given-names>S</given-names></name><name><surname>Yothers</surname><given-names>G</given-names></name><name><surname>Haller</surname><given-names>DG</given-names></name><name><surname>Gray</surname><given-names>R</given-names></name><name><surname>Benedetti</surname><given-names>J</given-names></name><collab>ACCENT Group</collab><etal></etal></person-group><article-title>End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>4569</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.10.4323</pub-id><pub-id pub-id-type="pmid">17876008</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Shigeta K, Hasegawa H, Okabayashi K, Tsuruta M, Ishii Y, Endo T, et al. Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer. Int J Cancer. 2016;139:946–54.</mixed-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scalamogna</surname><given-names>R</given-names></name><name><surname>Brugnatelli</surname><given-names>S</given-names></name><name><surname>Tinelli</surname><given-names>C</given-names></name><name><surname>Sagrada</surname><given-names>P</given-names></name><name><surname>Gattoni</surname><given-names>E</given-names></name><name><surname>Tronconi</surname><given-names>MC</given-names></name><etal></etal></person-group><article-title>UFT as maintenance therapy in patients with advanced colorectal cancer responsive to the FOLFOX4 regimen</article-title><source>Oncology.</source><year>2007</year><volume>72</volume><fpage>267</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1159/000113037</pub-id><pub-id pub-id-type="pmid">18187947</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>RM</given-names></name><name><surname>Sargent</surname><given-names>DJ</given-names></name><name><surname>Morton</surname><given-names>RF</given-names></name><name><surname>Fuchs</surname><given-names>CS</given-names></name><name><surname>Ramanathan</surname><given-names>RK</given-names></name><name><surname>Williamson</surname><given-names>SK</given-names></name><etal></etal></person-group><article-title>A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer</article-title><source>J Clin Oncol.</source><year>2004</year><volume>22</volume><fpage>23</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1200/JCO.2004.09.046</pub-id><pub-id pub-id-type="pmid">14665611</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators</collab></person-group><article-title>Efficacy of adjuvant fluorouracil and folinic acid in colon cancer</article-title><source>Lancet</source><year>1995</year><volume>345</volume><fpage>939</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(95)90696-7</pub-id><pub-id pub-id-type="pmid">7715291</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolmark</surname><given-names>N</given-names></name><name><surname>Rockette</surname><given-names>H</given-names></name><name><surname>Mamounas</surname><given-names>E</given-names></name><name><surname>Jones</surname><given-names>J</given-names></name><name><surname>Wieand</surname><given-names>S</given-names></name><name><surname>Wickerham</surname><given-names>DL</given-names></name><etal></etal></person-group><article-title>Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04</article-title><source>J Clin Oncol.</source><year>1999</year><volume>17</volume><fpage>3553</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1200/JCO.1999.17.11.3553</pub-id><pub-id pub-id-type="pmid">10550154</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>André</surname><given-names>T</given-names></name><name><surname>Boni</surname><given-names>C</given-names></name><name><surname>Mounedji-Boudiaf</surname><given-names>L</given-names></name><name><surname>Navarro</surname><given-names>M</given-names></name><name><surname>Tabernero</surname><given-names>J</given-names></name><name><surname>Hickish</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer</article-title><source>N Engl J Med</source><year>2004</year><volume>350</volume><fpage>2343</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa032709</pub-id><pub-id pub-id-type="pmid">15175436</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bennouna</surname><given-names>J</given-names></name><name><surname>Saunders</surname><given-names>M</given-names></name><name><surname>Douillard</surname><given-names>JY</given-names></name></person-group><article-title>The Role of UFT in metastatic colorectal cancer</article-title><source>Oncology.</source><year>2009</year><volume>76</volume><fpage>301</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1159/000209334</pub-id><pub-id pub-id-type="pmid">19299903</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>KD</given-names></name><name><surname>Lee</surname><given-names>SI</given-names></name><name><surname>Moon</surname><given-names>HY</given-names></name></person-group><article-title>The efficacy of oral tegafur-uracil as maintenance therapy following intravenous 5-fluorouracil chemotherapy in stage III colon cancer</article-title><source>Hepatogastroenterology.</source><year>2012</year><volume>59</volume><fpage>104</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">22251527</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gamelin</surname><given-names>E</given-names></name><name><surname>Gamelin</surname><given-names>L</given-names></name><name><surname>Bossi</surname><given-names>L</given-names></name><name><surname>Quasthoff</surname><given-names>S</given-names></name></person-group><article-title>Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures</article-title><source>Semin Oncol.</source><year>2002</year><volume>29</volume><fpage>21</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1053/sonc.2002.35525</pub-id><pub-id pub-id-type="pmid">12422305</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Hu JM, Chou YC, Wu CC, Hsiao CW, Lee CC, Chen CT, et al. Adjuvant chemotherapy with tegafur/uracil for more than 1 year improves disease-free survival for low-risk stage II colon cancer. J Chin Med Assoc. 2016;79(9):477–88.</mixed-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>YS</given-names></name><name><surname>Tsai</surname><given-names>HL</given-names></name><name><surname>Ma</surname><given-names>CJ</given-names></name><name><surname>Wu</surname><given-names>DC</given-names></name><name><surname>Lu</surname><given-names>CY</given-names></name><name><surname>Wu</surname><given-names>IC</given-names></name><name><surname>Hou</surname><given-names>MF</given-names></name><name><surname>Wang</surname><given-names>JY</given-names></name></person-group><article-title>A retrospective study of the safety and efficacy of a first-line treatment with mFOLFOX-4 in unresectable advanced or recurrent gastric cancer patients</article-title><source>Chemotherapy.</source><year>2012</year><volume>58</volume><fpage>411</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1159/000345742</pub-id><pub-id pub-id-type="pmid">23306825</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lou</surname><given-names>YT</given-names></name><name><surname>Chen</surname><given-names>CW</given-names></name><name><surname>Fan</surname><given-names>YC</given-names></name><name><surname>Chang</surname><given-names>WC</given-names></name><name><surname>Lu</surname><given-names>CY</given-names></name><name><surname>Wu</surname><given-names>IC</given-names></name><name><surname>Hsu</surname><given-names>WH</given-names></name><name><surname>Huang</surname><given-names>CW</given-names></name><name><surname>Wang</surname><given-names>JY</given-names></name></person-group><article-title>LINE-1 methylation status correlates significantly to post-therapeutic recurrence in stage III colon cancer patients receiving FOLFOX-4 adjuvant chemotherapy</article-title><source>PLoS One.</source><year>2015</year><volume>10</volume><fpage>e0123973</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0123973</pub-id><pub-id pub-id-type="pmid">25919688</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>AW</given-names></name><name><surname>Tetzlaff</surname><given-names>JM</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Laupacis</surname><given-names>A</given-names></name><name><surname>Gøtzsche</surname><given-names>PC</given-names></name><name><surname>Krleža-Jerić</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>SPIRIT 2013 Statement: defining standard protocol items for clinical trials</article-title><source>Ann Intern Med.</source><year>2013</year><volume>158</volume><fpage>200</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-158-3-201302050-00583</pub-id><pub-id pub-id-type="pmid">23295957</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>AW</given-names></name><name><surname>Tetzlaff</surname><given-names>JM</given-names></name><name><surname>Gøtzsche</surname><given-names>PC</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Mann</surname><given-names>H</given-names></name><name><surname>Berlin</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>SPIRIT 2013 Explanation and Elaboration: guidance for protocols of clinical trials</article-title><source>BMJ.</source><year>2013</year><volume>346</volume><fpage>e7586</fpage><pub-id pub-id-type="doi">10.1136/bmj.e7586</pub-id><pub-id pub-id-type="pmid">23303884</pub-id></element-citation></ref></ref-list></back></article>